Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy

Abstract

Since the United States Food and Drug Administration approved the first immune checkpoint inhibitor ipilimumab for metastatic melanoma in 2011, ICIs have been approved for a range of cancers and significantly improving treatment outcomes. However, the objective response rate of ICI monotherapy remains modest (10–40%), with clinical benefit observed in only 15–20% of patients. The limited efficacy of ICIs in many patients is often attributed to poorly immunogenic (“cold”) tumors. Radiotherapy and chemotherapy exhibit immunomodulatory properties that can enhance tumor immunogenicity. These effects provide a rationale for combining ICIs with conventional therapies. Current research lacks systematic synthesis and consistent clinical evidence on the immunomodulatory effects of radio/chemotherapy, and the optimal selection and sequencing of radio/chemotherapy with immunotherapy remain unclear, limiting the optimization of combination strategies with immunotherapy. This review outlines the current landscape of cancer immunotherapy and elucidates the immunomodulatory effects of radiotherapy and chemotherapy that form the basis for combination strategies. It further summarizes clinical advances in combined modalities and discusses associated toxicities, management approaches, and potential predictive biomarkers. This review provides a comprehensive framework for understanding and optimizing radio/chemo-immunotherapy by integrating mechanistic insights with clinical evidence to guide future personalized cancer treatment strategies.

Keywords

immunomodulatory effects / immunotherapy / radiotherapy / tumor / Chemotherapy

References

[1] P. Sharma, K. Wagner, J. D. Wolchok, and J. P. Allison, “Novel Cancer Immunotherapy Agents With Survival Benefit: Recent Successes and Next Steps,” Nature Reviews Cancer 11 (2011): 805-812.

[2] P. Sharma, B. A. Siddiqui, S. Anandhan, et al., “The Next Decade of Immune Checkpoint Therapy,” Cancer Discovery 11 (2021): 838-857.

[3] K. M. Cappell, J. N. Kochenderfer, “Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far,” Nature Reviews Clinical Oncology 20 (2023): 359-371.

[4] M. Reck, D. Rodríguez-Abreu, A. G. Robinson, et al., “Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer,” New England Journal of Medicine 375 (2016): 1823-1833.

[5] R. L. Ferris, G. Blumenschein, J. Fayette, et al., “Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck,” New England Journal of Medicine 375 (2016): 1856-1867.

[6] A. Dart, “New Targets for Cancer Immunotherapy,” Nature Reviews Cancer 18 (2018): 667.

[7] A. Ribas, J. D. Wolchok, “Cancer Immunotherapy Using Checkpoint Blockade,” Science 359 (2018): 1350-1355.

[8] S. L. Topalian, F. S. Hodi, J. R. Brahmer, et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” New England Journal of Medicine 366 (2012): 2443-2454.

[9] J. E. Rosenberg, J. Hoffman-Censits, T. Powles, et al., “Atezolizumab in Patients With Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed Following Treatment With Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial,” Lancet 387 (2016): 1909-1920.

[10] E. B. Garon, N. A. Rizvi, R. Hui, et al., “Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer,” New England Journal of Medicine 372 (2015): 2018-2028.

[11] S. Mishima, H. Taniguchi, K. Akagi, et al., “Japan Society of Clinical Oncology Provisional Clinical Opinion for the Diagnosis and Use of Immunotherapy in Patients With Deficient DNA Mismatch Repair Tumors, Cooperated by Japanese Society of Medical Oncology, First Edition,” International Journal of Clinical Oncology 25 (2020): 217-239.

[12] J. R. Brahmer, S. S. Tykodi, L. Q. Chow, et al., “Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer,” New England Journal of Medicine 366 (2012): 2455-2465.

[13] J. Galon, D. Bruni, “Approaches to Treat Immune Hot, Altered and Cold Tumours With Combination Immunotherapies,” Nat Rev Drug Discovery 18 (2019): 197-218.

[14] R. S. Herbst, J. C. Soria, M. Kowanetz, et al., “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients,” Nature 515 (2014): 563-567.

[15] P. C. Tumeh, C. L. Harview, J. H. Yearley, et al., “PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance,” Nature 515 (2014): 568-571.

[16] J. D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, et al., “Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 377 (2017): 1345-1356.

[17] M. McLaughlin, E. C. Patin, M. Pedersen, et al., “Inflammatory Microenvironment Remodelling by Tumour Cells After Radiotherapy,” Nature Reviews Cancer 20 (2020): 203-217.

[18] S. P. Kubli, T. Berger, D. V. Araujo, L. L. Siu, and T. W. Mak, “Beyond Immune Checkpoint Blockade: Emerging Immunological Strategies,” Nat Rev Drug Discovery 20 (2021): 899-919.

[19] M. Yi, X. Zheng, M. Niu, S. Zhu, H. Ge, and K. Wu, “Combination Strategies With PD-1/PD-L1 Blockade: Current Advances and Future Directions,” Molecular Cancer 21 (2022): 28.

[20] S. Liu, Q. Sun, X. Ren, “Novel Strategies for Cancer Immunotherapy: Counter-Immunoediting Therapy,” Journal of Hematology & Oncology 16 (2023): 38.

[21] R. R. Weichselbaum, H. Liang, L. Deng, and Y. X. Fu, “Radiotherapy and Immunotherapy: A Beneficial Liaison?,” Nature Reviews Clinical Oncology 14 (2017): 365-379.

[22] M. Orth, K. Lauber, M. Niyazi, et al., “Current Concepts in Clinical Radiation Oncology,” Radiation and Environmental Biophysics 53 (2014): 1-29.

[23] P. J. Hoskin, I. S. Bhattacharya, “Protons and More: State of the Art in Radiotherapy,” Clinical Medicine (London) 14, Suppl no. 6 (2014): s61-s65.

[24] J. Xu, J. Escamilla, S. Mok, et al., “CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer,” Cancer Research 73 (2013): 2782-2794.

[25] Y. Muroyama, T. R. Nirschl, C. M. Kochel, et al., “Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment,” Cancer Immunology Research 5 (2017): 992-1004.

[26] S. J. Dovedi, A. L. Adlard, G. Lipowska-Bhalla, et al., “Acquired Resistance to Fractionated Radiotherapy Can be Overcome by Concurrent PD-L1 Blockade,” Cancer Research 74 (2014): 5458-5468.

[27] H. Menon, R. Ramapriyan, T. R. Cushman, et al., “Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment,” Frontiers in Immunology 10 (2019): 193.

[28] J.-D. Fumet, E. Limagne, M. Thibaudin, and F. Ghiringhelli, “Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy,” Cancers 12 (2020): 2637.

[29] D. Alizadeh, N. Larmonier, “Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells,” Cancer Research 74 (2014): 2663-2668.

[30] L. Galluzzi, M. J. Aryankalayil, C. N. Coleman, and S. C. Formenti, “Emerging Evidence for Adapting Radiotherapy to Immunotherapy,” Nature Reviews Clinical Oncology 20 (2023): 543-557.

[31] R. Zagozdzon, J. Golab, “Immunomodulation by Anticancer Chemotherapy: More Is Not Always Better,” International Journal of Oncology 18 (2001): 417-424.

[32] A. Hallqvist, H. Koyi, L. de Petris, et al., “63MO Safety Analysis of Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Early-Stage Non-Small Cell Lung Cancer (NSCLC) Patients: A First Report of a Randomized Phase II Trial (ASTEROID),” Journal of Thoracic Oncology 16 (2021): S729-S730.

[33] S. Gadgeel, D. Rodríguez-Abreu, G. Speranza, et al., “Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology 38 (2020): 1505-1517.

[34] J. D. Schoenfeld, A. Giobbie-Hurder, S. Ranasinghe, et al., “Durvalumab Plus Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD (L)-1 Therapy: An Open-Label, Multicentre, Randomised, Phase 2 Trial,” The Lancet Oncology 23 (2022): 279-291.

[35] K. Rajani, C. Parrish, T. Kottke, et al., “Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses,” Molecular Therapy 24 (2016): 166-174.

[36] D. J. Propper, F. R. Balkwill, “Harnessing Cytokines and Chemokines for Cancer Therapy,” Nature Reviews Clinical Oncology 19 (2022): 237-253.

[37] D. Briukhovetska, J. Dörr, S. Endres, P. Libby, C. A. Dinarello, and S. Kobold, “Interleukins in Cancer: From Biology to Therapy,” Nature Reviews Cancer 21 (2021): 481-499.

[38] T. A. Waldmann, “Cytokines in Cancer Immunotherapy,” Cold Spring Harbor Perspectives in Biology 10 (2018): a028472.

[39] Y. Yang, A. Lundqvist, “Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy,” Cancers 12 (2020): 3586.

[40] G. Fyfe, R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson, and A. C. Louie, “Results of Treatment of 255 Patients With Metastatic Renal Cell Carcinoma Who Received High-Dose Recombinant Interleukin-2 Therapy,” Journal of Clinical Oncology 13 (1995): 688-696.

[41] K. C. Conlon, M. D. Miljkovic, T. A. Waldmann, “Cytokines in the Treatment of Cancer,” Journal of Interferon & Cytokine Research 39 (2019): 6-21.

[42] J. M. Kirkwood, M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum, “Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” Journal of Clinical Oncology 14 (1996): 7-17.

[43] H. C. Hasselbalch, M. O. Holmström, “Perspectives on Interferon-Alpha in the Treatment of Polycythemia Vera and Related Myeloproliferative Neoplasms: Minimal Residual Disease and Cure?,” Seminars in Immunopathology 41, no. 1 (2019): 5-19. Springer.

[44] J. How, G. Hobbs, “Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature,” Cancers 12 (2020): 1954.

[45] M. C. Duggan, C. Jochems, R. N. Donahue, et al., “A Phase I Study of Recombinant (r)Vaccinia-CEA (6D)-TRICOM and rFowlpox-CEA (6D)-TRICOM Vaccines With GM-CSF and IFN-α-2b in Patients With CEA-Expressing Carcinomas,” Cancer Immunology, Immunotherapy 65 (2016): 1353-1364.

[46] Y. Qiu, M. Su, L. Liu, Y. Tang, Y. Pan, and J. Sun, “Clinical Application of Cytokines in Cancer Immunotherapy,” Drug Design, Development and Therapy 15 (2021): 2269-2287.

[47] A. S. Bhagwat, L. Torres, O. Shestova, et al., “Cytokine-Mediated CAR T Therapy Resistance in AML,” Nature Medicine 30 (2024): 3697-3708.

[48] A. Tarhini, Y. Lin, H. Lin, et al., “Neoadjuvant Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-α2b in Locally/Regionally Advanced Melanoma: Safety, Efficacy and Impact on T-Cell Repertoire,” Journal for Immunotherapy of Cancer 6 (2018): 1-10.

[49] A. S. Brohl, N. I. Khushalani, Z. Eroglu, et al., “A Phase IB Study of Ipilimumab With Peginterferon Alfa-2b in Patients With Unresectable Melanoma,” Journal for ImmunoTherapy of Cancer 4 (2016): 85.

[50] J. R. Lange, A. A. Raubitschek, B. A. Pockaj, et al., “A Pilot Study of the Combination of Interleukin-2-Based Immunotherapy and Radiation Therapy,” Journal of Immunotherapy (1991) 12 (1992): 265-271.

[51] L. Ridolfi, F. de Rosa, R. Ridolfi, et al., “Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-Dose Interleukin-2: Evaluation of Biomarkers of Immunologic and Therapeutic Response,” Journal of Translational Medicine 12 (2014): 262.

[52] E. Vacchelli, A. Eggermont, W. H. Fridman, et al., “Trial Watch: Immunostimulatory Cytokines,” Oncoimmunology 2 (2013): e24850.

[53] S. J. Russell, K.-W. Peng, J. C. Bell, “Oncolytic Virotherapy,” Nature Biotechnology 30 (2012): 658-670.

[54] H. Fukuhara, Y. Ino, T. Todo, “Oncolytic Virus Therapy: A New Era of Cancer Treatment at Dawn,” Cancer Science 107 (2016): 1373-1379.

[55] S. E. Lawler, M.-C. Speranza, C.-F. Cho, and E. A. Chiocca, “Oncolytic Viruses in Cancer Treatment: A Review,” JAMA Oncology 3 (2017): 841-849.

[56] S. Z. Shalhout, D. M. Miller, K. S. Emerick, and H. L. Kaufman, “Therapy With Oncolytic Viruses: Progress and Challenges,” Nature Reviews Clinical Oncology 20 (2023): 160-177.

[57] R. H. Andtbacka, H. L. Kaufman, F. Collichio, et al., “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma,” Journal of Clinical Oncology 33 (2015): 2780-2788.

[58] Z.-J. Xia, J.-H. Chang, L. Zhang, et al., “Phase III Randomized Clinical Trial of Intratumoral Injection of E1B Gene-Deleted Adenovirus (H101) Combined With Cisplatin-Based Chemotherapy in Treating Squamous Cell Cancer of Head and Neck or Esophagus,” Ai Zheng = Aizheng = Chinese Journal of Cancer 23 (2004): 1666-1670.

[59] J. C. Hu, R. S. Coffin, C. J. Davis, et al., “A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor,” Clinical Cancer Research 12 (2006): 6737-6747.

[60] N. N. Senzer, H. L. Kaufman, T. Amatruda, et al., “Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma,” Journal of Clinical Oncology 27 (2009): 5763-5771.

[61] M. Aghi, S. Rabkin, R. L. Martuza, “Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication,” JNCI: Journal of the National Cancer Institute 98 (2006): 38-50.

[62] M. Muthana, S. Rodrigues, Y. Y. Chen, et al., “Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis After Chemotherapy or Irradiation,” Cancer Research 73 (2013): 490-495.

[63] M. J. Lin, J. Svensson-Arvelund, G. S. Lubitz, et al., “Cancer Vaccines: The Next Immunotherapy Frontier,” Nature Cancer 3 (2022): 911-926.

[64] W. B. Coley, “The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas: With a Report of Ten Original Cases. 1,” The American Journal of the Medical Sciences (1827-1924) 105 (1893): 487.

[65] H. C. Hoover, M. G. Surdyke, R. B. Dangel, L. C. Peters, and M. G. Hanna, “Prospectively Randomized Trial of Adjuvant Active-Specific Immunotherapy for Human Colorectal Cancer,” Cancer 55 (1985): 1236-1243.

[66] P. van der Bruggen, C. Traversari, P. Chomez, et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma,” Science 254 (1991): 1643-1647.

[67] B. Gaugler, B. Van den Eynde, P. van der Bruggen, et al., “Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes,” Journal of Experimental Medicine 179 (1994): 921-930.

[68] Z. Hu, P. A. Ott, C. J. Wu, “Towards Personalized, Tumour-Specific, Therapeutic Vaccines for Cancer,” Nature Reviews Immunology 18 (2018): 168-182.

[69] L. Novellino, C. Castelli, G. Parmiani, “A Listing of Human Tumor Antigens Recognized by T Cells: March 2004 Update,” Cancer Immunology, Immunotherapy 54 (2005): 187-207.

[70] C. J. Melief, T. van Hall, R. Arens, F. Ossendorp, and S. H. van der Burg, “Therapeutic Cancer Vaccines,” The Journal of Clinical Investigation 125 (2015): 3401-3412.

[71] J. Vansteenkiste, M. Zielinski, A. Linder, et al., “Adjuvant MAGE-A3 Immunotherapy in Resected Non-Small-Cell Lung Cancer: Phase II Randomized Study Results,” Journal of Clinical Oncology 31 (2013): 2396-2403.

[72] S. Jung, D. Unutmaz, P. Wong, et al., “In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens,” Immunity 17 (2002): 211-220.

[73] P. W. Kantoff, Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.

[74] P. Parsonidis, I. Papasotiriou, “Adoptive Cellular Transfer Immunotherapies for Cancer,” Cancer Treatment and Research Communications 32 (2022): 100575.

[75] N. Mitchison, “Studies on the Immunological Response to Foreign Tumor Transplants in the Mouse: I. The Role of Lymph Node Cells in Conferring Immunity by Adoptive Transfer,” The Journal of Experimental Medicine 102 (1955): 157-177.

[76] S. A. Rosenberg, W. D. Terry, “Passive Immunotherapy of Cancer in Animals and Man,” Advances in Cancer Research 25 (1977): 323-388.

[77] A. Fefer, “Immunotherapy and Chemotherapy of Moloney Sarcoma Virus-Induced Tumors in Mice,” Cancer Research 29 (1969): 2177-2183.

[78] S. A. Rosenberg, P. Spiess, R. Lafreniere, “A New Approach to the Adoptive Immunotherapy of Cancer With Tumor-Infiltrating Lymphocytes,” Science 233 (1986): 1318-1321.

[79] S. A. Rosenberg, J. R. Yannelli, J. C. Yang, et al., “Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2,” JNCI: Journal of the National Cancer Institute 86 (1994): 1159-1166.

[80] S. A. Rosenberg, N. P. Restifo, “Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer,” Science 348 (2015): 62-68.

[81] G. Gross, G. Gorochov, T. Waks, and Z. Eshhar, “Generation of Effector T Cells Expressing Chimeric T Cell Receptor With Antibody Type-Specificity,” Transplantation Proceedings 21, no. 1 Pt 1 (1989): 127-130.

[82] D. Moritz, W. Wels, J. Mattern, and B. Groner, “Cytotoxic T Lymphocytes With a Grafted Recognition Specificity for ERBB2-Expressing Tumor Cells,” Proceedings of the National Academy of Sciences 91 (1994): 4318-4322.

[83] P. Hwu, G. Shafer, J. Treisman, et al., “Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected With a Chimeric Gene Composed of an Antibody Variable Region and the Fc Receptor Gamma Chain,” Journal of Experimental Medicine 178 (1993): 361-366.

[84] C. H. Lamers, S. Sleijfer, A. G. Vulto, et al., “Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience,” Journal of Clinical Oncology 24 (2006): e20-e22.

[85] A. Krause, H.-F. Guo, J.-B. Latouche, C. Tan, N.-K. V. Cheung, and M. Sadelain, “Antigen-Dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes,” The Journal of Experimental Medicine 188 (1998): 619-626.

[86] J. Maher, R. J. Brentjens, G. Gunset, I. Rivière, and M. Sadelain, “Human T-Lymphocyte Cytotoxicity and Proliferation Directed by a Single Chimeric TCRζ/CD28 Receptor,” Nature Biotechnology 20 (2002): 70-75.

[87] B. Savoldo, C. A. Ramos, E. Liu, et al., “CD28 Costimulation Improves Expansion and Persistence of Chimeric Antigen Receptor-Modified T Cells in Lymphoma Patients,” The Journal of Clinical Investigation 121 (2011): 1822-1826.

[88] H. M. Finney, A. N. Akbar, A. D. Lawson, “Activation of Resting Human Primary T Cells With Chimeric Receptors: Costimulation From CD28, Inducible Costimulator, CD134, and CD137 in Series With Signals From the TCRζ Chain,” The Journal of Immunology 172 (2004): 104-113.

[89] C. Imai, K. Mihara, M. Andreansky, et al., “Chimeric Receptors With 4-1BB Signaling Capacity Provoke Potent Cytotoxicity Against Acute Lymphoblastic Leukemia,” Leukemia 18 (2004): 676-684.

[90] M. C. Milone, J. D. Fish, C. Carpenito, et al., “Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy in Vivo,” Molecular Therapy 17 (2009): 1453-1464.

[91] C. Tong, Y. Zhang, Y. Liu, et al., “Optimized Tandem CD19/CD20 CAR-Engineered T Cells in Refractory/Relapsed B-Cell Lymphoma. Blood,” The Journal of the American Society of Hematology 136 (2020): 1632-1644.

[92] P. Sharma, J. P. Allison, “Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies With Curative Potential,” Cell 161 (2015): 205-214.

[93] P. Sharma, J. P. Allison, “The Future of Immune Checkpoint Therapy,” Science 348 (2015): 56-61.

[94] D. M. Pardoll, “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews Cancer 12 (2012): 252-264.

[95] L. Chen, D. B. Flies, “Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition,” Nature Reviews Immunology 13 (2013): 227-242.

[96] T. L. Walunas, D. J. Lenschow, C. Y. Bakker, et al., “CTLA-4 Can Function as a Negative Regulator of T Cell Activation,” Immunity 1 (1994): 405-413.

[97] K.-M. Lee, E. Chuang, M. Griffin, et al., “Molecular Basis of T Cell Inactivation by CTLA-4,” Science 282 (1998): 2263-2266.

[98] V. K. Sondak, K. S. Smalley, R. Kudchadkar, S. Grippon, and P. Kirkpatrick, “Ipilimumab,” Nature Reviews Drug Discovery 10 (2011): 411-412.

[99] T. Okazaki, T. Honjo, “The PD-1-PD-L Pathway in Immunological Tolerance,” Trends in Immunology 27 (2006): 195-201.

[100] N. Patsoukis, J. S. Duke-Cohan, A. Chaudhri, et al., “Interaction of SHP-2 SH2 Domains With PD-1 ITSM Induces PD-1 Dimerization and SHP-2 Activation,” Communications Biology 3 (2020): 128.

[101] A. T. Parsa, J. S. Waldron, A. Panner, et al., “Loss of Tumor Suppressor PTEN Function Increases B7-H1 Expression and Immunoresistance in Glioma,” Nature Medicine 13 (2007): 84-88.

[102] K. Kato, B. C. Cho, M. Takahashi, et al., “Nivolumab Versus Chemotherapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology 20 (2019): 1506-1517.

[103] C. M. Fares, E. M. Van Allen, C. G. Drake, J. P. Allison, and S. Hu-Lieskovan, Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for all Patients?, American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2019, pp. 147-164.

[104] A. J. Schoenfeld, M. D. Hellmann, “Acquired Resistance to Immune Checkpoint Inhibitors,” Cancer Cell 37 (2020): 443-455.

[105] S. Vafaei, A. O. Zekiy, R. A. Khanamir, et al., “Combination Therapy With Immune Checkpoint Inhibitors (ICIs); a New Frontier,” Cancer Cell International 22 (2022): 1-27.

[106] G. Delaney, S. Jacob, C. Featherstone, and M. Barton, “The Role of Radiotherapy in Cancer Treatment: Estimating Optimal Utilization From a Review of Evidence-Based Clinical Guidelines,” Cancer 104 (2005): 1129-1137.

[107] W. L. Santivasi, F. Xia, “Ionizing Radiation-Induced DNA Damage, Response, and Repair,” Antioxid Redox Signaling 21 (2014): 251-259.

[108] Z. Li, X. Lai, S. Fu, et al., “Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency,” Advanced Science (Weinh) 9 (2022): e2201734.

[109] L. Karapetyan, U. K. Iheagwara, A. C. Olson, S. J. Chmura, H. K. Skinner, and J. J. Luke, “Radiation Dose, Schedule, and Novel Systemic Targets for Radio-Immunotherapy Combinations,” JNCI: Journal of the National Cancer Institute 115 (2023): 1278-1293.

[110] R. H. Mole, “Whole Body Irradiation; Radiobiology or Medicine?,” The British Journal of Radiology 26 (1953): 234-241.

[111] S. Demaria, B. Ng, M. L. Devitt, et al., “Ionizing Radiation Inhibition of Distant Untreated Tumors (Abscopal Effect) Is Immune Mediated,” International Journal of Radiation and Oncology in Biology and Physics 58 (2004): 862-870.

[112] W. Ngwa, O. C. Irabor, J. D. Schoenfeld, J. Hesser, S. Demaria, and S. C. Formenti, “Using Immunotherapy to Boost the Abscopal Effect,” Nature Reviews Cancer 18 (2018): 313-322.

[113] M. Ochoa de Olza, J. Bourhis, M. Irving, G. Coukos, and F. G. Herrera, “High Versus Low Dose Irradiation for Tumor Immune Reprogramming,” Current Opinion in Biotechnology 65 (2020): 268-283.

[114] N. E. Donlon, R. Power, C. Hayes, J. V. Reynolds, and J. Lysaght, “Radiotherapy, Immunotherapy, and the Tumour Microenvironment: Turning an Immunosuppressive Milieu Into a Therapeutic Opportunity,” Cancer Letters 502 (2021): 84-96.

[115] A. Sharma, B. Bode, R. H. Wenger, et al., “γ-Radiation Promotes Immunological Recognition of Cancer Cells Through Increased Expression of Cancer-Testis Antigens in Vitro and in Vivo,” PLoS ONE 6 (2011): e28217.

[116] E. A. Reits, J. W. Hodge, C. A. Herberts, et al., “Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy,” Journal of Experimental Medicine 203 (2006): 1259-1271.

[117] C. Lhuillier, N. P. Rudqvist, O. Elemento, S. C. Formenti, and S. Demaria, “Radiation Therapy and Anti-Tumor Immunity: Exposing Immunogenic Mutations to the Immune System,” Genome Medicine 11 (2019): 40.

[118] S. J. Haikerwal, J. Hagekyriakou, M. MacManus, O. A. Martin, and N. M. Haynes, “Building Immunity to Cancer With Radiation Therapy,” Cancer Letters 368 (2015): 198-208.

[119] M. de Charette, A. Marabelle, R. Houot, “Turning Tumour Cells Into Antigen Presenting Cells: The Next Step to Improve Cancer Immunotherapy?,” European Journal of Cancer 68 (2016): 134-147.

[120] K. Mortezaee, M. Najafi, “Immune System in Cancer Radiotherapy: Resistance Mechanisms and Therapy Perspectives,” Critical Reviews in Oncology/Hematology 157 (2021): 103180.

[121] G. Navarro, M. Gómez-Autet, P. Morales, et al., “Homodimerization of CB(2) Cannabinoid Receptor Triggered by a Bivalent Ligand Enhances Cellular Signaling,” Pharmacological Research 208 (2024): 107363.

[122] R. Fan, A. Deng, R. Lin, et al., “A Platinum (IV)-Artesunate Complex Triggers Ferroptosis by Boosting Cytoplasmic and Mitochondrial Lipid Peroxidation to Enhance Tumor Immunotherapy,” MedComm 5 (2024): e570.

[123] D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic Cell Death and DAMPs in Cancer Therapy,” Nature Reviews Cancer 12 (2012): 860-875.

[124] G. Kroemer, C. Galassi, L. Zitvogel, and L. Galluzzi, “Immunogenic Cell Stress and Death,” Nature Immunology 23 (2022): 487-500.

[125] A. D. Garg, P. Agostinis, “Cell Death and Immunity in Cancer: From Danger Signals to Mimicry of Pathogen Defense Responses,” Immunological Reviews 280 (2017): 126-148.

[126] L. I. Gold, P. Eggleton, M. T. Sweetwyne, et al., “Calreticulin: Non-Endoplasmic Reticulum Functions in Physiology and Disease,” The FASEB Journal 24 (2010): 665-683.

[127] T. Panaretakis, O. Kepp, U. Brockmeier, et al., “Mechanisms of Pre-Apoptotic Calreticulin Exposure in Immunogenic Cell Death,” The EMBO Journal 28 (2009): 578-590.

[128] M. Kielbik, I. Szulc-Kielbik, M. Klink, “Calreticulin-Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients,” Cells 10 (2021).

[129] M. Obeid, T. Panaretakis, N. Joza, et al., “Calreticulin Exposure Is Required for the Immunogenicity of Gamma-Irradiation and UVC Light-Induced Apoptosis,” Cell Death and Differentiation 14 (2007): 1848-1850.

[130] M. Obeid, A. Tesniere, F. Ghiringhelli, et al., “Calreticulin Exposure Dictates the Immunogenicity of Cancer Cell Death,” Nature Medicine 13 (2007): 54-61.

[131] G. Multhoff, “Hyperthermia Classic Commentary: Activation of Natural Killer (NK) Cells by Heat Shock Protein 70, Gabriele Multhoff, International Journal of Hyperthermia, 2002;18:576-585,” International Journal of Hyperthermia 25 (2009): 176-179.

[132] R. Wang, T. Town, V. Gokarn, R. A. Flavell, and R. Y. Chandawarkar, “HSP70 Enhances Macrophage Phagocytosis by Interaction With Lipid Raft-Associated TLR-7 and Upregulating p38 MAPK and PI3K Pathways,” Journal of Surgical Research 136 (2006): 58-69.

[133] R. Chen, R. Kang, D. Tang, “The Mechanism of HMGB1 Secretion and Release,” Experimental & Molecular Medicine 54 (2022): 91-102.

[134] D. G. Perregaux, P. McNiff, R. Laliberte, M. Conklyn, and C. A. Gabel, “ATP Acts as an Agonist to Promote Stimulus-Induced Secretion of IL-1 Beta and IL-18 in Human Blood,” Journal of Immunology 165 (2000): 4615-4623.

[135] L. Apetoh, F. Ghiringhelli, A. Tesniere, et al., “The Interaction Between HMGB1 and TLR4 Dictates the Outcome of Anticancer Chemotherapy and Radiotherapy,” Immunological Reviews 220 (2007): 47-59.

[136] R. Saenz, D. Futalan, L. Leutenez, et al., “TLR4-Dependent Activation of Dendritic Cells by an HMGB1-Derived Peptide Adjuvant,” Journal of translational medicine 12 (2014): 211.

[137] M. Michaud, I. Martins, A. Q. Sukkurwala, et al., “Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice,” Science 334 (2011): 1573-1577.

[138] M. R. Elliott, F. B. Chekeni, P. C. Trampont, et al., “Nucleotides Released by Apoptotic Cells Act as a Find-Me Signal to Promote Phagocytic Clearance,” Nature 461 (2009): 282-286.

[139] R. D. Leone, L. A. Emens, “Targeting Adenosine for Cancer Immunotherapy,” Journal for ImmunoTherapy of Cancer 6 (2018): 57.

[140] A. Ahmed, S. W. G. Tait, “Targeting Immunogenic Cell Death in Cancer,” Molecular Oncology 14 (2020): 2994-3006.

[141] B. L. Rapoport, R. Anderson, “Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy,” International Journal of Molecular Sciences 20, no. 4 (2019): 959.

[142] D. Djureinovic, M. Wang, H. M. Kluger, “Agonistic CD40 Antibodies in Cancer Treatment,” Cancers (Basel) 13, no. 6 (2021): 1302.

[143] U. S. Gaipl, G. Multhoff, H. Scheithauer, et al., “Kill and Spread the Word: Stimulation of Antitumor Immune Responses in the Context of Radiotherapy,” Immunotherapy 6 (2014): 597-610.

[144] B. Zunino, C. Rubio-Patiño, E. Villa, et al., “Hyperthermic Intraperitoneal Chemotherapy Leads to an Anticancer Immune Response via Exposure of Cell Surface Heat Shock Protein 90,” Oncogene 35 (2016): 261-268.

[145] K. J. Mackenzie, P. Carroll, C. A. Martin, et al., “cGAS Surveillance of Micronuclei Links Genome Instability to Innate Immunity,” Nature 548 (2017): 461-465.

[146] L. Deng, H. Liang, M. Xu, et al., “STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors,” Immunity 41 (2014): 843-852.

[147] A. Deng, R. Fan, Y. Hai, et al., “A STING Agonist Prodrug Reprograms Tumor-Associated Macrophage to Boost Colorectal Cancer Immunotherapy,” Theranostics 15 (2025): 277.

[148] Q. Chen, L. Sun, Z. J. Chen, “Regulation and Function of the cGAS-STING Pathway of Cytosolic DNA Sensing,” Nature Immunology 17 (2016): 1142-1149.

[149] L. Sun, J. Wu, F. Du, X. Chen, and Z. J. Chen, “Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway,” Science 339 (2013): 786-791.

[150] B. J. Francica, A. Ghasemzadeh, A. L. Desbien, et al., “TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors,” Cancer Immunology Research 6 (2018): 422-433.

[151] J. A. Carozza, V. Böhnert, K. C. Nguyen, et al., “Extracellular cGAMP Is a Cancer Cell-Produced Immunotransmitter Involved in Radiation-Induced Anti-Cancer Immunity,” Nature Cancer 1 (2020): 184-196.

[152] Y. Bao, Z. Pan, L. Zhao, et al., “BIBR1532 Combined With Radiotherapy Induces Ferroptosis in NSCLC Cells and Activates cGAS-STING Pathway to Promote Anti-Tumor Immunity,” Journal of Translational Medicine 22 (2024): 519.

[153] M. Li, J. Xiao, S. Song, et al., “PREX2 Contributes to Radiation Resistance by Inhibiting Radiotherapy-Induced Tumor Immunogenicity via cGAS/STING/IFNs Pathway in Colorectal Cancer,” BMC Medicine [Electronic Resource] 22 (2024): 154.

[154] C. Zhang, Z. Deng, J. Wu, et al., “HO-1 Impairs the Efficacy of Radiotherapy by Redistributing cGAS and STING in Tumors,” Journal of Clinical Investigation 134, no. 23 (2024): e181044.

[155] C. Wen, L. Wang, A. Piffkó, et al., “YTHDF1 Loss in Dendritic Cells Potentiates Radiation-Induced Antitumor Immunity via STING-Dependent Type I IFN Production,” Journal of Clinical Investigation 134, no. 23 (2024): e181612.

[156] G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, “Immunogenic Cell Death in Cancer Therapy,” Annual Review of Immunology 31 (2013): 51-72.

[157] X. Xiao, S. Liang, Y. Zhao, et al., “Multifunctional Carbon Monoxide Nanogenerator as Immunogenic Cell Death Drugs With Enhanced Antitumor Immunity and Antimetastatic Effect,” Biomaterials 277 (2021): 121120.

[158] S. Ji, J. Li, X. Duan, et al., “Targeted Enrichment of Enzyme-Instructed Assemblies in Cancer Cell Lysosomes Turns Immunologically Cold Tumors Hot,” Angewandte Chemie (International ed in English) 60 (2021): 26994-27004.

[159] M. Rückert, A. S. Flohr, M. Hecht, and U. S. Gaipl, “Radiotherapy and the Immune System: More Than Just Immune Suppression,” Stem Cells 39 (2021): 1155-1165.

[160] M. Charpentier, S. Spada, S. J. Van Nest, and S. Demaria, “Radiation Therapy-Induced Remodeling of the Tumor Immune Microenvironment,” Seminars in Cancer Biology 86 (2022): 737-747.

[161] I. Telarovic, C. S. M. Yong, M. Guckenberger, J. Unkelbach, and M. Pruschy, “Radiation-Induced Lymphopenia Does Not Impact Treatment Efficacy in a Mouse Tumor Model,” Neoplasia 31 (2022): 100812.

[162] N. Nakamura, Y. Kusunoki, M. Akiyama, “Radiosensitivity of CD4 or CD8 Positive Human T-Lymphocytes by an in Vitro Colony Formation Assay,” Radiation Research 123 (1990): 224-227.

[163] D. Dai, Q. Tian, Y. Shui, J. Li, and Q. Wei, “The Impact of Radiation Induced Lymphopenia in the Prognosis of Head and Neck Cancer: A Systematic Review and Meta-Analysis,” Radiotherapy and Oncology 168 (2022): 28-36.

[164] P. J. J. Damen, T. E. Kroese, R. van Hillegersberg, et al., “The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis,” International Journal of Radiation and Oncology in Biology and Physics 111 (2021): 936-948.

[165] R. Upadhyay, B. P. Venkatesulu, P. Giridhar, et al., “Risk and Impact of Radiation Related Lymphopenia in Lung Cancer: A Systematic Review and Meta-Analysis,” Radiotherapy and Oncology 157 (2021): 225-233.

[166] J. Liu, Q. Zhao, W. Deng, et al., “Radiation-Related Lymphopenia Is Associated With Spleen Irradiation Dose During Radiotherapy in Patients With Hepatocellular Carcinoma,” Radiation Oncology 12 (2017): 90.

[167] H. E. Barker, J. T. Paget, A. A. Khan, and K. J. Harrington, “The Tumour Microenvironment After Radiotherapy: Mechanisms of Resistance and Recurrence,” Nature Reviews Cancer 15 (2015): 409-425.

[168] W. H. Fridman, F. Pagès, C. Sautès-Fridman, and J. Galon, “The Immune Contexture in Human Tumours: Impact on Clinical Outcome,” Nature Reviews Cancer 12 (2012): 298-306.

[169] S. V. Kozin, W. S. Kamoun, Y. Huang, M. R. Dawson, R. K. Jain, and D. G. Duda, “Recruitment of Myeloid but Not Endothelial Precursor Cells Facilitates Tumor Regrowth After Local Irradiation,” Cancer Research 70 (2010): 5679-5685.

[170] M. Kioi, H. Vogel, G. Schultz, R. M. Hoffman, G. R. Harsh, and J. M. Brown, “Inhibition of Vasculogenesis, but Not Angiogenesis, Prevents the Recurrence of Glioblastoma After Irradiation in Mice,” Journal of Clinical Investigation 120 (2010): 694-705.

[171] X. Wang, X. Yang, Y. Tsai, et al., “IL-6 Mediates Macrophage Infiltration After Irradiation via Up-Regulation of CCL2/CCL5 in Non-Small Cell Lung Cancer,” Radiation Research 187 (2017): 50-59.

[172] A. Facciabene, G. T. Motz, G. Coukos, “T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis,” Cancer Research 72 (2012): 2162-2171.

[173] M. H. Barcellos-Hoff, R. Derynck, M. L. Tsang, and J. A. Weatherbee, “Transforming Growth Factor-Beta Activation in Irradiated Murine Mammary Gland,” Journal of Clinical Investigation 93 (1994): 892-899.

[174] T. L. YWang, J. Lv, L. Xiao, Mechanism of Increased Treg Frequency Induced by Irradiated Esophageal Squamous Cell Carcinoma, 2021.

[175] M. Mondini, P. L. Loyher, P. Hamon, et al., “CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated With TNFα-Mediated Resistance,” Cancer Immunology Research 7 (2019): 376-387.

[176] C. Zhang, Z. Liang, S. Ma, and X. Liu, “Radiotherapy and Cytokine Storm: Risk and Mechanism,” Frontiers in Oncology 11 (2021): 670464.

[177] A. J. Oweida, L. Darragh, A. Phan, et al., “STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer,” JNCI: Journal of the National Cancer Institute 111 (2019): 1339-1349.

[178] D. Ji, C. Song, Y. Li, et al., “Combination of Radiotherapy and Suppression of Tregs Enhances Abscopal Antitumor Effect and Inhibits Metastasis in Rectal Cancer,” Journal for ImmunoTherapy of Cancer 8 (2020).

[179] D. I. Gabrilovich, S. Nagaraj, “Myeloid-Derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology 9 (2009): 162-174.

[180] T. Condamine, I. Ramachandran, J. I. Youn, and D. I. Gabrilovich, “Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells,” Annual Review of Medicine 66 (2015): 97-110.

[181] D. Marvel, D. I. Gabrilovich, “Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Expect the Unexpected,” Journal of Clinical Investigation 125 (2015): 3356-3364.

[182] K. Movahedi, M. Guilliams, J. Van den Bossche, et al., “Identification of Discrete Tumor-Induced Myeloid-Derived Suppressor Cell Subpopulations With Distinct T Cell-Suppressive Activity,” Blood 111 (2008): 4233-4244.

[183] D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G. J. Adema, “The Immunosuppressive Tumour Network: Myeloid-Derived Suppressor Cells, Regulatory T Cells and Natural Killer T Cells,” Immunology 138 (2013): 105-115.

[184] E. Wennerberg, C. Lhuillier, C. Vanpouille-Box, et al., “Barriers to Radiation-Induced in Situ Tumor Vaccination,” Frontiers in Immunology 8 (2017): 229.

[185] S. Demaria, E. B. Golden, S. C. Formenti, “Role of Local Radiation Therapy in Cancer Immunotherapy,” JAMA Oncology 1 (2015): 1325-1332.

[186] H. Liang, L. Deng, Y. Hou, et al., “Host STING-Dependent MDSC Mobilization Drives Extrinsic Radiation Resistance,” Nature Communications 8 (2017): 1736.

[187] Z. Zhang, Z. Yao, Z. Zhang, et al., “Local Radiotherapy for Murine Breast Cancer Increases Risk of Metastasis by Promoting the Recruitment of M-MDSCs in Lung,” Cancer Cell International 23 (2023): 107.

[188] N. Dehne, J. Mora, D. Namgaladze, A. Weigert, and B. Brüne, “Cancer Cell and Macrophage Cross-Talk in the Tumor Microenvironment,” Current Opinion in Pharmacology 35 (2017): 12-19.

[189] A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, “Tumour-Associated Macrophages Are a Distinct M2 Polarised Population Promoting Tumour Progression: Potential Targets of Anti-Cancer Therapy,” European Journal of Cancer 42 (2006): 717-727.

[190] O. Sezginer, N. Unver, “Dissection of Pro-Tumoral Macrophage Subtypes and Immunosuppressive Cells Participating in M2 Polarization,” Inflammation Research 73 (2024): 1411-1423.

[191] M. M. Leblond, E. A. Pérès, C. Helaine, et al., “M2 Macrophages Are More Resistant Than M1 Macrophages Following Radiation Therapy in the Context of Glioblastoma,” Oncotarget 8 (2017): 72597-72612.

[192] R. Ostuni, F. Kratochvill, P. J. Murray, and G. Natoli, “Macrophages and Cancer: From Mechanisms to Therapeutic Implications,” Trends in Immunology 36 (2015): 229-239.

[193] C. Becherini, A. Lancia, B. Detti, et al., “Modulation of Tumor-Associated Macrophage Activity With Radiation Therapy: A Systematic Review,” Strahlentherapie Und Onkologie 199 (2023): 1173-1190.

[194] F. Klug, H. Prakash, P. E. Huber, et al., “Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS⁺/M1 Phenotype That Orchestrates Effective T Cell Immunotherapy,” Cancer Cell 24 (2013): 589-602.

[195] P. Gascard, T. D. Tlsty, “Carcinoma-Associated Fibroblasts: Orchestrating the Composition of Malignancy,” Genes & Development 30 (2016): 1002-1019.

[196] R. Kalluri, “The Biology and Function of Fibroblasts in Cancer,” Nature Reviews Cancer 16 (2016): 582-598.

[197] G. Ishii, A. Ochiai, S. Neri, “Phenotypic and Functional Heterogeneity of Cancer-Associated Fibroblast Within the Tumor Microenvironment,” Advanced Drug Delivery Reviews 99 (2016): 186-196.

[198] S. Goruppi, G. P. Dotto, “Mesenchymal Stroma: Primary Determinant and Therapeutic Target for Epithelial Cancer,” Trends in Cell Biology 23 (2013): 593-602.

[199] M. E. Fiori, S. Di Franco, L. Villanova, P. Bianca, G. Stassi, and R. De Maria, “Cancer-Associated Fibroblasts as Abettors of Tumor Progression at the Crossroads of EMT and Therapy Resistance,” Molecular Cancer 18 (2019): 70.

[200] A. E. Denton, E. W. Roberts, D. T. Fearon, “Stromal Cells in the Tumor Microenvironment,” Advances in Experimental Medicine and Biology 1060 (2018): 99-114.

[201] Y. Kojima, A. Acar, E. N. Eaton, et al., “Autocrine TGF-Beta and Stromal Cell-Derived Factor-1 (SDF-1) Signaling Drives the Evolution of Tumor-Promoting Mammary Stromal Myofibroblasts,” PNAS 107 (2010): 20009-20014.

[202] Z. Wang, Y. Tang, Y. Tan, Q. Wei, and W. Yu, “Cancer-Associated Fibroblasts in Radiotherapy: Challenges and New Opportunities,” Cell Communication and Signaling 17 (2019): 47.

[203] J. Barbazán, D. Matic Vignjevic, “Cancer Associated Fibroblasts: Is the Force the Path to the Dark Side?,” Current Opinion in Cell Biology 56 (2019): 71-79.

[204] M. T. Grinde, J. Vik, K. A. Camilio, I. Martinez-Zubiaurre, and T. Hellevik, “Ionizing Radiation Abrogates the Pro-Tumorigenic Capacity of Cancer-Associated Fibroblasts Co-Implanted in Xenografts,” Scientific Reports 7 (2017): 46714.

[205] B. A. Chabner, T. G. Roberts, “Chemotherapy and the War on Cancer,” Nature Reviews Cancer 5 (2005): 65-72.

[206] D. Galmarini, C. M. Galmarini, F. C. Galmarini, “Cancer Chemotherapy: A Critical Analysis of Its 60 Years of History,” Critical Reviews in Oncology/Hematology 84 (2012): 181-199.

[207] P. Nygren, “What Is Cancer Chemotherapy?,” Acta Oncologica 40 (2001): 166-174.

[208] L. Galluzzi, A. Buque, O. Kepp, L. Zitvogel, and G. Kroemer, “Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents,” Cancer Cell 28 (2015): 690-714.

[209] C. Pfirschke, C. Engblom, S. Rickelt, et al., “Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy,” Immunity 44 (2016): 343-354.

[210] L. Galluzzi, J. Humeau, A. Buqué, L. Zitvogel, and G. Kroemer, “Immunostimulation With Chemotherapy in the Era of Immune Checkpoint Inhibitors,” Nature Reviews Clinical Oncology 17 (2020): 725-741.

[211] C. Hernandez, P. Huebener, R. F. Schwabe, “Damage-Associated Molecular Patterns in Cancer: A Double-Edged Sword,” Oncogene 35 (2016): 5931-5941.

[212] Y. Ma, S. Adjemian, S. R. Mattarollo, et al., “Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells,” Immunity 38 (2013): 729-741.

[213] I. Martins, Y. Wang, M. Michaud, et al., “Molecular Mechanisms of ATP Secretion During Immunogenic Cell Death,” Cell Death & Differentiation 21 (2014): 79-91.

[214] T. Yamazaki, D. Hannani, V. Poirier-Colame, et al., “Defective Immunogenic Cell Death of HMGB1-Deficient Tumors: Compensatory Therapy With TLR4 Agonists,” Cell Death & Differentiation 21 (2014): 69-78.

[215] Z. Wang, J. Chen, J. Hu, et al., “cGAS/STING Axis Mediates a Topoisomerase II Inhibitor-Induced Tumor Immunogenicity,” The Journal of Clinical Investigation 129 (2019): 4850-4862.

[216] A. Sistigu, T. Yamazaki, E. Vacchelli, et al., “Cancer Cell-Autonomous Contribution of Type I Interferon Signaling to the Efficacy of Chemotherapy,” Nature Medicine 20 (2014): 1301-1309.

[217] N. Casares, M. O. Pequignot, A. Tesniere, et al., “Caspase-Dependent Immunogenicity of Doxorubicin-Induced Tumor Cell Death,” Journal of Experimental Medicine 202 (2005): 1691-1701.

[218] O. Kepp, L. Senovilla, I. Vitale, et al., “Consensus Guidelines for the Detection of Immunogenic Cell Death,” Oncoimmunology 3 (2014): e955691.

[219] T. Qin, X. Xu, Z. Zhang, et al., “Paclitaxel/Sunitinib-Loaded Micelles Promote an Antitumor Response in Vitro Through Synergistic Immunogenic Cell Death for Triple-Negative Breast Cancer,” Nanotechnology 31 (2020): 365101.

[220] A. Tesniere, F. Schlemmer, V. Boige, et al., “Immunogenic Death of Colon Cancer Cells Treated With Oxaliplatin,” Oncogene 29 (2010): 482-491.

[221] J. Wang, H. Zhang, X. Yin, and Y. Bian, “Oxaliplatin Induces Immunogenic Cell Death in Human and Murine Laryngeal Cancer,” Journal of Oncology 2022 (2022): 3760766.

[222] I. Martins, O. Kepp, F. Schlemmer, et al., “Restoration of the Immunogenicity of Cisplatin-Induced Cancer Cell Death by Endoplasmic Reticulum Stress,” Oncogene 30 (2011): 1147-1158.

[223] O. Mukherjee, S. Rakshit, G. Shanmugam, and K. Sarkar, “Role of Chemotherapeutic Drugs in Immunomodulation of Cancer,” Current Research in Immunology 4 (2023): 100068.

[224] D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, “New Insights Into Cancer Immunoediting and Its Three Component Phases—Elimination, Equilibrium and Escape,” Current Opinion in Immunology 27 (2014): 16-25.

[225] R. Nowarski, N. Gagliani, S. Huber, and R. A. Flavell, “Innate Immune Cells in Inflammation and Cancer,” Cancer Immunology Research 1 (2013): 77-84.

[226] L. Apetoh, F. Ghiringhelli, A. Tesniere, et al., “Toll-Like Receptor 4-Dependent Contribution of the Immune System to Anticancer Chemotherapy and Radiotherapy,” Nature Medicine 13 (2007): 1050-1059.

[227] F. Ghiringhelli, L. Apetoh, A. Tesniere, et al., “Activation of the NLRP3 Inflammasome in Dendritic Cells Induces IL-1β-Dependent Adaptive Immunity Against Tumors,” Nature Medicine 15 (2009): 1170-1178.

[228] C. Bergmann, H. S. Bachmann, A. Bankfalvi, et al., “Toll-Like Receptor 4 Single-Nucleotide Polymorphisms Asp299Gly and Thr399Ile in Head and Neck Squamous Cell Carcinomas,” Journal of Translational Medicine 9 (2011): 1-9.

[229] E. Vacchelli, L. Galluzzi, V. Rousseau, et al., “Loss-of-Function Alleles of P2RX7 and TLR4 Fail to Affect the Response to Chemotherapy in Non-Small Cell Lung Cancer,” Oncoimmunology 1 (2012): 271-278.

[230] C. T. Weaver, E. R. Unanue, “The Costimulatory Function of Antigen-Presenting Cells,” Immunology Today 11 (1990): 49-55.

[231] C. J. Melief, “Cancer Immunotherapy by Dendritic Cells,” Immunity 29 (2008): 372-383.

[232] H. Tanaka, H. Matsushima, N. Mizumoto, and A. Takashima, “Classification of Chemotherapeutic Agents Based on Their Differential in Vitro Effects on Dendritic Cells,” Cancer Research 69 (2009): 6978-6986.

[233] A. M. McDonnell, W. J. Lesterhuis, A. Khong, et al., “Tumor-Infiltrating Dendritic Cells Exhibit Defective Cross-Presentation of Tumor Antigens, but Is Reversed by Chemotherapy,” European Journal of Immunology 45 (2015): 49-59.

[234] A. K. Nowak, B. W. Robinson, R. A. Lake, “Synergy Between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors,” Cancer Research 63 (2003): 4490-4496.

[235] S. Trojandt, D. Knies, S. Pektor, et al., “The Chemotherapeutic Agent Topotecan Differentially Modulates the Phenotype and Function of Dendritic Cells,” Cancer Immunology, Immunotherapy 62 (2013): 1315-1326.

[236] J. Crawford, D. C. Dale, G. H. Lyman, “Chemotherapy-Induced Neutropenia: Risks, Consequences, and New Directions for Its Management,” Cancer 100 (2004): 228-237.

[237] J. N. Barreto, K. B. McCullough, L. L. Ice, and J. A. Smith, “Antineoplastic Agents and the Associated Myelosuppressive Effects: A Review,” Journal of Pharmacy Practice 27 (2014): 440-446.

[238] A. M. Cook, W. J. Lesterhuis, A. K. Nowak, and R. A. Lake, “Chemotherapy and Immunotherapy: Mapping the Road Ahead,” Current Opinion in Immunology 39 (2016): 23-29.

[239] J.-Y. Li, X.-F. Duan, L.-P. Wang, et al., “Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients With Nonsmall Cell Lung Cancer,” Journal of Immunology Research 2014 (2014): 286170.

[240] M. Awwad, R. North, “Cyclophosphamide (Cy)-Facilitated Adoptive Immunotherapy of a Cy-Resistant Tumour. Evidence That Cy Permits the Expression of Adoptive T-Cell Mediated Immunity by Removing Suppressor T Cells Rather Than by Reducing Tumour Burden,” Immunology 65 (1988): 87.

[241] R. J. North, “Cyclophosphamide-Facilitated Adoptive Immunotherapy of an Established Tumor Depends on Elimination of Tumor-Induced Suppressor T Cells,” The Journal of Experimental Medicine 155 (1982): 1063-1074.

[242] Y. Ge, C. Domschke, N. Stoiber, et al., “Metronomic Cyclophosphamide Treatment in Metastasized Breast Cancer Patients: Immunological Effects and Clinical Outcome,” Cancer Immunology, Immunotherapy 61 (2012): 353-362.

[243] J. Zhao, Y. Cao, Z. Lei, Z. Yang, B. Zhang, and B. Huang, “Selective Depletion of CD4+ CD25+ Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide is Explained by Reduced Intracellular ATP Levels,” Cancer Research 70 (2010): 4850-4858.

[244] M. T. Madondo, M. Quinn, M. Plebanski, “Low Dose Cyclophosphamide: Mechanisms of T Cell Modulation,” Cancer Treatment Reviews 42 (2016): 3-9.

[245] S. Dimeloe, C. Frick, M. Fischer, et al., “Human Regulatory T Cells Lack the Cyclophosphamide-Extruding Transporter ABCB 1 and Are More Susceptible to Cyclophosphamide-Induced Apoptosis,” European Journal of Immunology 44 (2014): 3614-3620.

[246] X. Chen, Y. Yang, Q. Zhou, et al., “Effective Chemoimmunotherapy With Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer,” PLoS ONE 9 (2014): e85398.

[247] R. Wesolowski, M. C. Duggan, A. Stiff, et al., “Circulating Myeloid-Derived Suppressor Cells Increase in Patients Undergoing Neo-Adjuvant Chemotherapy for Breast Cancer,” Cancer Immunology, Immunotherapy 66 (2017): 1437-1447.

[248] Z. Wang, Y. Liu, Y. Zhang, Y. Shang, and Q. Gao, “MDSC-Decreasing Chemotherapy Increases the Efficacy of Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Cell Carcinoma and Pancreatic Cancer,” Oncotarget 7 (2015): 4760.

[249] S. L. Highfill, Y. Cui, A. J. Giles, et al., “Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy,” Science Translational Medicine 6 (2014): 237ra67.

[250] A. Sevko, T. Michels, M. Vrohlings, et al., “Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model,” The Journal of Immunology 190 (2013): 2464-2471.

[251] M. Bruchard, G. Mignot, V. Derangère, et al., “Chemotherapy-Triggered Cathepsin B Release in Myeloid-Derived Suppressor Cells Activates the Nlrp3 Inflammasome and Promotes Tumor Growth,” Nature Medicine 19 (2013): 57-64.

[252] Z.-C. Ding, X. Lu, M. Yu, et al., “Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses Through the PD-1-PD-L1 Axis,” Cancer Research 74 (2014): 3441-3453.

[253] A. Sica, A. Mantovani, “Macrophage Plasticity and Polarization: In Vivo Veritas,” The Journal of Clinical Investigation 122 (2012): 787-795.

[254] C. W. Wanderley, D. F. Colon, J. P. M. Luiz, et al., “Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner,” Cancer Research 78 (2018): 5891-5900.

[255] A. Javeed, M. Ashraf, A. Riaz, A. Ghafoor, S. Afzal, and M. M. Mukhtar, “Paclitaxel and Immune System,” European Journal of Pharmaceutical Sciences 38 (2009): 283-290.

[256] I. Larionova, N. Cherdyntseva, T. Liu, M. Patysheva, M. Rakina, and J. Kzhyshkowska, “Interaction of Tumor-Associated Macrophages and Cancer Chemotherapy,” Oncoimmunology 8 (2019): e1596004.

[257] C. Allen, S. Her, D. A. Jaffray, “Radiotherapy for Cancer: Present and Future,” Advanced Drug Delivery Reviews 109 (2017): 1-2.

[258] L. K. Spary, S. Al-Taei, J. Salimu, et al., “Enhancement of T Cell Responses as a Result of Synergy Between Lower Doses of Radiation and T Cell Stimulation,” Journal of Immunology 192 (2014): 3101-3110.

[259] C. H. Sonn, J. R. Choi, T. J. Kim, et al., “Augmentation of Natural Cytotoxicity by Chronic Low-Dose Ionizing Radiation in Murine Natural Killer Cells Primed by IL-2,” The Journal of Radiation Research 53 (2012): 823-829.

[260] G. Yang, Q. Kong, G. Wang, et al., “Low-Dose Ionizing Radiation Induces Direct Activation of Natural Killer Cells and Provides a Novel Approach for Adoptive Cellular Immunotherapy,” Cancer Biotherapy & Radiopharmaceuticals 29 (2014): 428-434.

[261] A. Cheda, J. Wrembel-Wargocka, E. Lisiak, E. M. Nowosielska, M. Marciniak, and M. K. Janiak, “Single Low Doses of X Rays Inhibit the Development of Experimental Tumor Metastases and Trigger the Activities of NK Cells in Mice,” Radiation Research 161 (2004): 335-340.

[262] M. Cao, R. Cabrera, Y. Xu, C. Liu, and D. Nelson, “Different Radiosensitivity of CD4(+)CD25(+) Regulatory T Cells and Effector T Cells to Low Dose Gamma Irradiation in Vitro,” International Journal of Radiation Biology 87 (2011): 71-80.

[263] F. G. Herrera, M. Irving, L. E. Kandalaft, and G. Coukos, “Rational Combinations of Immunotherapy With Radiotherapy in Ovarian Cancer,” The Lancet Oncology 20 (2019): e417-e433.

[264] F. G. Herrera, C. Ronet, M. Ochoa de Olza, et al., “Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy,” Cancer Discovery 12 (2022): 108-133.

[265] C. Vanpouille-Box, A. Alard, M. J. Aryankalayil, et al., “DNA Exonuclease Trex1 Regulates Radiotherapy-Induced Tumour Immunogenicity,” Nature Communications 8 (2017): 15618.

[266] C. Vanpouille-Box, S. C. Formenti, S. Demaria, “TREX1 Dictates the Immune Fate of Irradiated Cancer Cells,” Oncoimmunology 6 (2017): e1339857.

[267] D. Schaue, J. A. Ratikan, K. S. Iwamoto, and W. H. McBride, “Maximizing Tumor Immunity With Fractionated Radiation,” International Journal of Radiation and Oncology in Biology and Physics 83 (2012): 1306-1310.

[268] S. Swisher-McClure, N. Mitra, K. Woo, M. Smaldone, R. Uzzo, and J. E. Bekelman, “Increasing Use of Dose-Escalated External Beam Radiation Therapy for Men With Nonmetastatic Prostate Cancer,” International Journal of Radiation and Oncology in Biology and Physics 89 (2014): 103-112.

[269] A. Abravan, C. Faivre-Finn, J. Kennedy, A. McWilliam, and M. van Herk, “Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer,” Journal of Thoracic Oncology 15 (2020): 1624-1635.

[270] R. Timmerman, R. Paulus, J. Galvin, et al., “Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer,” Jama 303 (2010): 1070-1076.

[271] Y. Chen, M. Gao, Z. Huang, J. Yu, and X. Meng, “SBRT Combined With PD-1/PD-L1 Inhibitors in NSCLC Treatment: A Focus on the Mechanisms, Advances, and Future Challenges,” Journal of Hematology & Oncology 13 (2020): 105.

[272] S. S. Lo, A. J. Fakiris, E. L. Chang, et al., “Stereotactic Body Radiation Therapy: A Novel Treatment Modality,” Nature Reviews Clinical Oncology 7 (2010): 44-54.

[273] M. Ashrafizadeh, B. Farhood, A. Eleojo Musa, S. Taeb, A. Rezaeyan, and M. Najafi, “Abscopal Effect in Radioimmunotherapy,” International Immunopharmacology 85 (2020): 106663.

[274] M. Z. Dewan, A. E. Galloway, N. Kawashima, et al., “Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect When Combined With Anti-CTLA-4 Antibody,” Clinical Cancer Research 15 (2009): 5379-5388.

[275] S. Senan, C. G. Rusthoven, B. J. Slotman, and S. Siva, “Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017,” Journal of Thoracic Oncology 13 (2018): 488-496.

[276] D. von Reibnitz, F. Shaikh, A. J. Wu, et al., “Stereotactic Body Radiation Therapy (SBRT) Improves Local Control and Overall Survival Compared to Conventionally Fractionated Radiation for Stage I Non-Small Cell Lung Cancer (NSCLC),” Acta Oncologica 57 (2018): 1567-1573.

[277] A. M. Monjazeb, A. Giobbie-Hurder, A. Lako, et al., “A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition With Targeted Low-Dose or Hypofractionated Radiation for Patients With Metastatic Colorectal Cancer,” Clinical Cancer Research 27 (2021): 2470-2480.

[278] S. Yovino, L. Kleinberg, S. A. Grossman, M. Narayanan, and E. Ford, “The Etiology of Treatment-Related Lymphopenia in Patients With Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells,” Cancer Investigation 31 (2013): 140-144.

[279] A. T. Wild, J. M. Herman, A. S. Dholakia, et al., “Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer,” International Journal of Radiation and Oncology in Biology and Physics 94 (2016): 571-579.

[280] C. Tang, Z. Liao, D. Gomez, et al., “Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes,” International Journal of Radiation and Oncology in Biology and Physics 89 (2014): 1084-1091.

[281] A. B. Sharabi, M. Lim, T. L. DeWeese, and C. G. Drake, “Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy,” The Lancet Oncology 16 (2015): e498-e509.

[282] S. Kim, E. Wuthrick, D. Blakaj, et al., “Combined Nivolumab and Ipilimumab With or Without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma: A Randomised, Open Label, Phase 2 Trial,” Lancet 400 (2022): 1008-1019.

[283] Y. Liu, C. Meyer, A. Müller, et al., “IL-13 Induces Connective Tissue Growth Factor in Rat Hepatic Stellate Cells via TGF-β-Independent Smad Signaling,” Journal of Immunology 187 (2011): 2814-2823.

[284] J. W. Welsh, C. Tang, P. de Groot, et al., “Phase II Trial of Ipilimumab With Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses,” Cancer Immunology Research 7 (2019): 1903-1909.

[285] S. Shang, J. Liu, V. Verma, et al., “Combined Treatment of Non-Small Cell Lung Cancer Using Radiotherapy and Immunotherapy: Challenges and Updates,” Cancer Communications (Lond) 41 (2021): 1086-1099.

[286] C. W. Williamson, M. V. Sherer, D. Zamarin, et al., “Immunotherapy and Radiation Therapy Sequencing: State of the Data on Timing, Efficacy, and Safety,” Cancer 127 (2021): 1553-1567.

[287] H. Zhang, Z. Dai, W. Wu, et al., “Regulatory Mechanisms of Immune Checkpoints PD-L1 and CTLA-4 in Cancer,” Journal of Experimental & Clinical Cancer Research 40 (2021): 184.

[288] Y. Ban, G. J. Markowitz, Y. Zou, et al., “Radiation-Activated Secretory Proteins of Scgb1a1(+) Club Cells Increase the Efficacy of Immune Checkpoint Blockade in Lung Cancer,” Nature Cancer 2 (2021): 919-931.

[289] I. Verbrugge, J. Hagekyriakou, L. L. Sharp, et al., “Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies,” Cancer Research 72 (2012): 3163-3174.

[290] P. A. Ott, Z. Hu, D. B. Keskin, et al., “An Immunogenic Personal Neoantigen Vaccine for Patients With Melanoma,” Nature 547 (2017): 217-221.

[291] S. J. Dovedi, T. M. Illidge, “The Antitumor Immune Response Generated by Fractionated Radiation Therapy May be Limited by Tumor Cell Adaptive Resistance and Can be Circumvented by PD-L1 Blockade,” Oncoimmunology 4 (2015): e1016709.

[292] K. H. Young, J. R. Baird, T. Savage, et al., “Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy,” PLoS ONE 11 (2016): e0157164.

[293] J. Wei, W. Montalvo-Ortiz, L. Yu, et al., “Sequence of αPD-1 Relative to Local Tumor Irradiation Determines the Induction of Abscopal Antitumor Immune Responses,” Science Immunology 6, no. 58 (2021): eabg0117.

[294] W. Theelen, D. Chen, V. Verma, et al., “Pembrolizumab With or Without Radiotherapy for Metastatic Non-Small-Cell Lung Cancer: A Pooled Analysis of Two Randomised Trials,” The Lancet Respiratory Medicine 9 (2021): 467-475.

[295] S. J. Antonia, A. Villegas, D. Daniel, et al., “Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC,” New England Journal of Medicine 379 (2018): 2342-2350.

[296] S. J. Antonia, A. Villegas, D. Daniel, et al., “Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer,” New England Journal of Medicine 377 (2017): 1919-1929.

[297] C. Faivre-Finn, D. Vicente, T. Kurata, et al., “Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-An Update From the PACIFIC Trial,” Journal of Thoracic Oncology 16 (2021): 860-867.

[298] S. Peters, E. Felip, U. Dafni, et al., “Safety Evaluation of Nivolumab Added Concurrently to Radiotherapy in a Standard First Line Chemo-Radiotherapy Regimen in Stage III Non-Small Cell Lung Cancer-The ETOP NICOLAS Trial,” Lung Cancer 133 (2019): 83-87.

[299] E. E. Cohen, R. L. Ferris, A. Psyrri, et al., “910O Primary Results of the Phase III JAVELIN Head & Neck 100 Trial: Avelumab Plus Chemoradiotherapy (CRT) Followed by Avelumab Maintenance vs CRT in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN),” Annals of Oncology 31 (2020): S658.

[300] S. Siva, R. McMahon, M. Bressel, et al., “SABRSeq: A Randomized Phase Ib Trial of SABR Sequencing With Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (NSCLC),” International Journal of Radiation Oncology, Biology, Physics 117 (2023): e58.

[301] J. M. Varlotto, Z. Sun, S. S. Ramalingam, et al., “Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC: A Trial of the ECOG-ACRIN Cancer Research Group (EA5181),” Journal of Clinical Oncology 39 (2021): TPS8584.

[302] S. C. Formenti, N.-P. Rudqvist, E. Golden, et al., “Radiotherapy Induces Responses of Lung Cancer to CTLA-4 Blockade,” Nature Medicine 24 (2018): 1845-1851.

[303] H. J. Ross, D. Kozono, X. F. Wang, et al., “Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial,” JAMA Oncology 10 (2024): 1212-1219.

[304] S. H. Lin, S. L. Pugh, A. S. Tsao, et al., Safety Results of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With durvalumab in PD-L1-high Locally Advanced Non-small Cell Lung Cancer (American Society of Clinical Oncology, 2022).

[305] K. A. Ahmed, Y. Kim, J. A. Arrington, et al., “Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study,” Advances in Radiation Oncology 6 (2021): 100798.

[306] D. B. Page, K. Beal, S. N. Linch, et al., “Brain Radiotherapy, Tremelimumab-Mediated CTLA-4-Directed Blockade+/− Trastuzumab in Patients With Breast Cancer Brain Metastases,” NPJ Breast Cancer 8 (2022): 50.

[307] R. Barroso-Sousa, I. E. Krop, L. Trippa, et al., “A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-Positive Metastatic Breast Cancer,” Clinical Breast Cancer 20 (2020): 238-245.

[308] A. Y. Ho, C. A. Barker, B. B. Arnold, et al., “A Phase 2 Clinical Trial Assessing the Efficacy and Safety of Pembrolizumab and Radiotherapy in Patients With Metastatic Triple-Negative Breast Cancer,” Cancer 126 (2020): 850-860.

[309] L. Voorwerk, M. Slagter, H. M. Horlings, et al., “Immune Induction Strategies in Metastatic Triple-Negative Breast Cancer to Enhance the Sensitivity to PD-1 Blockade: The TONIC Trial,” Nature Medicine 25 (2019): 920-928.

[310] M. Takada, M. Yoshimura, T. Kotake, et al., “Phase Ib/II Study of Nivolumab Combined With Palliative Radiation Therapy for Bone Metastasis in Patients With HER2-Negative Metastatic Breast Cancer,” Scientific Reports 12 (2022): 22397.

[311] K. Sun, Y. Xu, L. Zhang, et al., “A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and in Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer,” Clinical Cancer Research 28 (2022): 4392-4401.

[312] S. David, P. Savas, S. Siva, et al., “Abstract PD10-02: A Randomised Phase II Trial of Single Fraction or Multi-Fraction SABR (Stereotactic Ablative Body Radiotherapy) With Atezolizumab in Patients With Advanced Triple Negative Breast Cancer (AZTEC Trial),” Cancer Research 82 (2022): PD10-02.

[313] H. McArthur, J. Cortés, R. Dent, et al., “Abstract PD3-01: Neoadjuvant Pembrolizumab+ Chemotherapy vs Placebo+ Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Post Hoc Analysis of Adjuvant Radiation Therapy in the Phase 3 KEYNOTE-522 Study,” Cancer Research 83 (2023): PD3-01-PD3-01.

[314] N. Y. Lee, R. L. Ferris, A. Psyrri, et al., “Avelumab Plus Standard-of-Care Chemoradiotherapy Versus Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Trial,” The Lancet Oncology 22 (2021): 450-462.

[315] J. Bourhis, Y. Tao, X. Sun, et al., “LBA35 Avelumab-Cetuximab-Radiotherapy Versus Standards of Care in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (LA-SCCHN): Randomized Phase III GORTEC-REACH Trial,” Annals of Oncology 32 (2021): S1310.

[316] J. Machiels, Y. Tao, B. Burtness, et al., “LBA5 Primary Results of the Phase III KEYNOTE-412 Study: Pembrolizumab (pembro) With Chemoradiation Therapy (CRT) vs Placebo Plus CRT for Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC),” Annals of Oncology 33 (2022): S1399.

[317] R. Haddad, D. Wong, Y. Guo, et al., “IMvoke010: Randomized Phase III Study of Atezolizumab (atezo) as Adjuvant Monotherapy After Definitive Therapy of Squamous Cell Carcinoma of the Head and Neck (SCCHN),” Annals of Oncology 29 (2018): viii397.

[318] R. Uppaluri, N. Y. Lee, W. Westra, et al., KEYNOTE-689: Phase 3 Study of Adjuvant and Neoadjuvant Pembrolizumab Combined With Standard of Care (SOC) in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (American Society of Clinical Oncology, 2019).

[319] H. B. Zech, N. Moeckelmann, A. Boettcher, et al., “Phase III Study of Nivolumab Alone or Combined With Ipilimumab as Immunotherapy Versus Standard of Care in Resectable Head and Neck Squamous Cell Carcinoma,” Future Oncology 16 (2020): 3035-3043.

[320] J. J. Luke, J. M. Lemons, T. G. Karrison, et al., “Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors,” Journal of Clinical Oncology 36 (2018): 1611-1618.

[321] S. McBride, E. Sherman, C. J. Tsai, et al., “Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma,” Journal of Clinical Oncology 39 (2021): 30-37.

[322] L. Duska, K. Romano, L. Holman, et al., “A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Cancer (005),” Gynecologic Oncology 176 (2023): S5.

[323] C. Garcia-Duran, F. Grau, G. Villacampa, and A. Oaknin, “ATOMICC Trial: A Randomized, Open-Label, Phase II Trial of Anti-PD1, Dostarlimab, as Maintenance Therapy for Patients With High-Risk Locally Advanced Cervical Cancer After Chemoradiation,” International Journal of Gynecological Cancer 32 (2022): 1196-1200.

[324] C. Twyman-Saint Victor, A. J. Rech, A. Maity, et al., “Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer,” Nature 520 (2015): 373-377.

[325] C. Tang, J. W. Welsh, P. De Groot, et al., “Ipilimumab With Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates From Peripheral T Cells,” Clinical Cancer Research 23 (2017): 1388-1396.

[326] A. Maity, R. Mick, A. C. Huang, et al., “A Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Metastatic Solid Tumours,” British Journal of Cancer 119 (2018): 1200-1207.

[327] S.-J. Park, W. Ye, R. Xiao, et al., “Cisplatin and Oxaliplatin Induce Similar Immunogenic Changes in Preclinical Models of Head and Neck Cancer,” Oral Oncology 95 (2019): 127-135.

[328] L. Guo, P. Song, X. Xue, et al., “Variation of Programmed Death Ligand 1 Expression After Platinum-Based Neoadjuvant Chemotherapy in Lung Cancer,” Journal of Immunotherapy 42 (2019): 215-220.

[329] J. Shin, J.-H. Chung, S. H. Kim, et al., “Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-Small Cell Lung Cancer,” Cancer Research and Treatment: Official Journal of Korean Cancer Association 51 (2019): 1086-1097.

[330] S. Grabosch, M. Bulatovic, F. Zeng, et al., “Cisplatin-Induced Immune Modulation in Ovarian Cancer Mouse Models With Distinct Inflammation Profiles,” Oncogene 38 (2019): 2380-2393.

[331] Y. Gilad, Y. Eliaz, Y. Yu, S. J. Han, B. W. O'Malley, and D. M. Lonard, “Drug-Induced PD-L1 Expression and Cell Stress Response in Breast Cancer Cells Can be Balanced by Drug Combination,” Scientific Reports 9 (2019): 15099.

[332] C. Grigg, N. A. Rizvi, “PD-L1 Biomarker Testing for Non-Small Cell Lung Cancer: Truth or Fiction?,” Journal for Immunotherapy of Cancer 4 (2016): 48.

[333] R. S. Herbst, M. Sznol, “Diminished but Not Dead: Chemotherapy for the Treatment of NSCLC,” The Lancet Oncology 17 (2016): 1464-1465.

[334] L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, et al., “Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer,” New England Journal of Medicine 378 (2018): 2078-2092.

[335] L. Paz-Ares, A. Luft, D. Vicente, et al., “Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer,” New England Journal of Medicine 379 (2018): 2040-2051.

[336] A. Mansfield, A. Każarnowicz, N. Karaseva, et al., “Safety and Patient-Reported Outcomes of Atezolizumab, Carboplatin, and Etoposide in Extensive-Stage Small-Cell Lung Cancer (IMpower133): A Randomized Phase I/III Trial,” Annals of Oncology 31 (2020): 310-317.

[337] L. G. Paz-Ares, M. Dvorkin, Y. Chen, et al., Durvalumab±Tremelimumab+ Platinum-etoposide in First-line Extensive-stage SCLC (ES-SCLC): Updated Results From the Phase III CASPIAN Study (American Society of Clinical Oncology, 2020).

[338] Y. Cheng, L. Han, L. Wu, et al., “Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial,” Jama 328 (2022): 1223-1232.

[339] M. Larroquette, C. Domblides, F. Lefort, et al., “Combining Immune Checkpoint Inhibitors With Chemotherapy in Advanced Solid Tumours: A Review,” European Journal of Cancer 158 (2021): 47-62.

[340] B. Burtness, K. J. Harrington, R. Greil, et al., “Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study,” The Lancet 394 (2019): 1915-1928.

[341] L. A. Emens, S. Adams, C. Barrios, et al., “First-Line Atezolizumab Plus Nab-Paclitaxel for Unresectable, Locally Advanced, or Metastatic Triple-Negative Breast Cancer: IMpassion130 Final Overall Survival Analysis,” Annals of Oncology 32 (2021): 983-993.

[342] P. Schmid, S. Adams, H. S. Rugo, et al., “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” New England Journal of Medicine 379 (2018): 2108-2121.

[343] G. Chen, L. A. Emens, “Chemoimmunotherapy: Reengineering Tumor Immunity,” Cancer Immunology, Immunotherapy 62 (2013): 203-216.

[344] J.-Y. Liu, Y. Wu, X.-S. Zhang, et al., “Single Administration of Low Dose Cyclophosphamide Augments the Antitumor Effect of Dendritic Cell Vaccine,” Cancer Immunology, Immunotherapy 56 (2007): 1597-1604.

[345] M. C. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom, and H. Sabzevari, “Inhibition of CD4+ 25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-Dose Cyclophosphamide,” Blood 105 (2005): 2862-2868.

[346] J. Taieb, N. Chaput, N. Schartz, et al., “Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes With Exosome Based Vaccines,” The Journal of Immunology 176 (2006): 2722-2729.

[347] H. Wu, Y. Xin, J. Zhao, et al., “Metronomic Docetaxel Chemotherapy Inhibits Angiogenesis and Tumor Growth in a Gastric Cancer Model,” Cancer Chemotherapy and Pharmacology 68 (2011): 879-887.

[348] C.-L. Chang, Y.-T. Hsu, C.-C. Wu, et al., “Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response,” Cancer Research 73 (2013): 119-127.

[349] G. V. Shurin, I. L. Tourkova, R. Kaneno, and M. R. Shurin, “Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism,” The Journal of Immunology 183 (2009): 137-144.

[350] H. Zhong, B. Han, I. L. Tourkova, et al., “Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth,” Clinical Cancer Research 13 (2007): 5455-5462.

[351] J. Liu, J. Zhao, L. Hu, Y. Cao, and B. Huang, “Low Dosages: New Chemotherapeutic Weapons on the Battlefield of Immune-Related Disease,” Cellular & Molecular Immunology 8 (2011): 289-295.

[352] C. Banissi, F. Ghiringhelli, L. Chen, and A. F. Carpentier, “Treg Depletion With a Low-Dose Metronomic Temozolomide Regimen in a Rat Glioma Model,” Cancer Immunology, Immunotherapy 58 (2009): 1627-1634.

[353] D. Laheru, E. Lutz, J. Burke, et al., “Allogeneic GM-CSF Secreting Tumor Immunotherapy (Gvax®) Alone or in Sequence With Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility and Immune Activation,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 14 (2008): 1455.

[354] S. Walter, T. Weinschenk, A. Stenzl, et al., “Multipeptide Immune Response to Cancer Vaccine IMA901 After Single-Dose Cyclophosphamide Associates With Longer Patient Survival,” Nature Medicine 18 (2012): 1254-1261.

[355] L. Bracci, G. Schiavoni, A. Sistigu, and F. Belardelli, “Immune-Based Mechanisms of Cytotoxic Chemotherapy: Implications for the Design of Novel and Rationale-Based Combined Treatments Against Cancer,” Cell Death & Differentiation 21 (2014): 15-25.

[356] P. M. Arlen, J. L. Gulley, C. Parker, et al., “A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer,” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 12 (2006): 1260-1269.

[357] E. H. Warren, N. Fujii, Y. Akatsuka, et al., “Therapy of Relapsed Leukemia After Allogeneic Hematopoietic Cell Transplantation With T Cells Specific for Minor Histocompatibility Antigens,” Blood 115 (2010): 3869-3878.

[358] M. E. Dudley, J. C. Yang, R. Sherry, et al., “Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens,” Journal of Clinical Oncology 26 (2008): 5233-5239.

[359] M. L. Salem, C. M. Díaz-Montero, A. A. Al-Khami, et al., “Recovery From Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses in Vivo When Stimulated With the TLR3 Agonist Poly (I: C),” The Journal of Immunology 182 (2009): 2030-2040.

[360] C. A. Chen, C. M. Ho, M. C. Chang, et al., “Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis,” Molecular Therapy 18 (2010): 1233-1243.

[361] I. F. Hermans, T. W. Chong, M. J. Palmowski, A. L. Harris, and V. Cerundolo, “Synergistic Effect of Metronomic Dosing of Cyclophosphamide Combined With Specific Antitumor Immunotherapy in a Murine Melanoma Model,” Cancer Research 63 (2003): 8408-8413.

[362] M. S. Nars, R. Kaneno, “Immunomodulatory Effects of Low Dose Chemotherapy and Perspectives of Its Combination With Immunotherapy,” International Journal of Cancer 132 (2013): 2471-2478.

[363] J. C. Doloff, D. J. Waxman, “VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression,” Cancer Research 72 (2012): 1103-1115.

[364] C.-S. Chen, J. C. Doloff, D. J. Waxman, “Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression,” Neoplasia 16 (2014): 84-W27.

[365] J. Wu, D. J. Waxman, “Metronomic Cyclophosphamide Schedule-Dependence of Innate Immune Cell Recruitment and Tumor Regression in an Implanted Glioma Model,” Cancer Letters 353 (2014): 272-280.

[366] J. Wu, D. J. Waxman, “Metronomic Cyclophosphamide Eradicates Large Implanted GL261 Gliomas by Activating Antitumor Cd8+ T-Cell Responses and Immune Memory,” Oncoimmunology 4 (2015): e1005521.

[367] S. Peng, S. Lyford-Pike, B. Akpeng, et al., “Low-Dose Cyclophosphamide Administered as Daily or Single Dose Enhances the Antitumor Effects of a Therapeutic HPV Vaccine,” Cancer Immunology, Immunotherapy 62 (2013): 171-182.

[368] F. Moschella, M. Valentini, E. Aricò, et al., “Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide,” Cancer Research 71 (2011): 3528-3539.

[369] F. Moschella, G. F. Torelli, M. Valentini, et al., “Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy,” Clinical Cancer Research 19 (2013): 4249-4261.

[370] S. Wada, K. Yoshimura, E. L. Hipkiss, et al., “Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model,” Cancer Research 69 (2009): 4309-4318.

[371] B. Palermo, D. Del Bello, A. Sottini, et al., “Dacarbazine Treatment Before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients,” Cancer Research 70 (2010): 7084-7092.

[372] S. J. Antonia, N. Mirza, I. Fricke, et al., “Combination of p53 Cancer Vaccine With Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer,” Clinical Cancer Research 12 (2006): 878-887.

[373] C. J. Wheeler, K. L. Black, G. Liu, et al., “Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients,” Cancer Research 68 (2008): 5955-5964.

[374] L. Paz-Ares, T.-E. Ciuleanu, M. Cobo, et al., “First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial,” The Lancet Oncology 22 (2021): 198-211.

[375] C. J. Langer, S. M. Gadgeel, H. Borghaei, et al., “Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study,” The Lancet Oncology 17 (2016): 1497-1508.

[376] S. Peters, S. Ramalingam, L. Paz-Ares, et al., “Nivolumab (NIVO)+ Low-Dose Ipilimumab (IPI) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): CheckMate 227 Part 1 Final Analysis,” Annals of Oncology 30 (2019): v913-v914.

[377] T. J. Lynch, I. Bondarenko, A. Luft, et al., “Ipilimumab in Combination With Paclitaxel and Carboplatin as First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study,” Journal of Clinical Oncology 30 (2012): 2046-2054.

[378] S. D. Kamath, A. Kalyan, S. Kircher, et al., “Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study,” The Oncologist 25 (2020): e808-e815.

[379] K. Feng, Y. Liu, Y. Zhao, et al., “Efficacy and Biomarker Analysis of Nivolumab Plus Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Biliary Tract Cancers: Results From a Phase II Study,” Journal for Immunotherapy of Cancer 8 (2020): e000367.

[380] Z. A. Wainberg, H. S. Hochster, E. J.-H. Kim, et al., Phase I Study of Nivolumab (Nivo)+ Nab-paclitaxel (nab-P)+ Gemcitabine (Gem) in Advanced Pancreatic Cancer (APC) (American Society of Clinical Oncology, 2019).

[381] P. Lara, L. Beckett, Y. Li, et al., Combination Checkpoint Immunotherapy and Cytotoxic Chemotherapy: Pembrolizumab (Pembro) plus either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Urothelial Cancer (American Society of Clinical Oncology, 2017).

[382] N. Yamazaki, H. Uhara, S. Fukushima, et al., “Phase II Study of the Immune-Checkpoint Inhibitor Ipilimumab Plus Dacarbazine in Japanese Patients With Previously Untreated, Unresectable or Metastatic Melanoma,” Cancer Chemotherapy and Pharmacology 76 (2015): 969-975.

[383] M. Reck, S. Liu, A. Mansfield, et al., “IMpower133: Updated Overall Survival (OS) Analysis of First-Line (1L) Atezolizumab (atezo)+ Carboplatin+ Etoposide in Extensive-Stage SCLC (ES-SCLC),” Annals of Oncology 30 (2019): v710-v711.

[384] P. Schmid, S. Adams, H. Rugo, et al., “IMpassion130: Results From a Global, Randomised, Double-Blind, Phase III Study of Atezolizumab (atezo)+ Nab-Paclitaxel (nab-P) vs Placebo+ Nab-P in Treatment-Naive, Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC),” Annals of Oncology 29 (2018): viii707-viii708.

[385] F. Cappuzzo, M. McCleod, M. Hussein, et al., “IMpower130: Progression-Free Survival (PFS) and Safety Analysis From a Randomised Phase III Study of Carboplatin+ Nab-Paclitaxel (CnP) With or Without Atezolizumab (atezo) as First-Line (1L) Therapy in Advanced Non-Squamous NSCLC,” Annals of Oncology 29 (2018): viii742-viii743.

[386] M. Reck, T.-E. Ciuleanu, M. C. Dols, et al., Nivolumab (NIVO)+ ipilimumab (IPI)+ 2 Cycles of Platinum-doublet Chemotherapy (chemo) vs 4 Cycles Chemo as First-line (1L) Treatment (tx) for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC): CheckMate 9LA (American Society of Clinical Oncology, 2020).

[387] M. L. Johnson, B. C. Cho, A. Luft, et al., “Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study,” Journal of Clinical Oncology 41 (2023): 1213-1227.

[388] Y. Y. Janjigian, A. Kawazoe, P. Yañez, et al., “The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer,” Nature 600 (2021): 727-730.

[389] Y. Y. Janjigian, K. Shitara, M. Moehler, et al., “First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial,” The Lancet 398 (2021): 27-40.

[390] J.-M. Sun, L. Shen, M. A. Shah, et al., “Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study,” The Lancet 398 (2021): 759-771.

[391] D.-Y. Oh, A. R. He, M. Bouattour, et al., “Durvalumab or Placebo Plus Gemcitabine and Cisplatin in Participants With Advanced Biliary Tract Cancer (TOPAZ-1): Updated Overall Survival From a Randomised Phase 3 Study,” The Lancet Gastroenterology & Hepatology 9 (2024): 694-704.

[392] I. Puzanov, M. M. Milhem, D. Minor, et al., “Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma,” Journal of Clinical Oncology 34 (2016): 2619-2626.

[393] F. S. Hodi, S. J. O'Day, D. F. McDermott, et al., “Improved Survival With Ipilimumab in Patients With Metastatic Melanoma,” New England Journal of Medicine 363 (2010): 711-723.

[394] M. Scholz, S. Yep, M. Chancey, et al., “Phase I Clinical Trial of Sipuleucel-T Combined With Escalating Doses of Ipilimumab in Progressive Metastatic Castrate-Resistant Prostate Cancer,” ImmunoTargets and Therapy (2017): 11-16.

[395] R. A. Madan, M. Mohebtash, P. M. Arlen, et al., “Ipilimumab and a Poxviral Vaccine Targeting Prostate-Specific Antigen in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Dose-Escalation Trial,” The Lancet Oncology 13 (2012): 501-508.

[396] T. Tsujikawa, T. Crocenzi, J. N. Durham, et al., “Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) With or Without Nivolumab in Patients With Pancreatic Cancer,” Clinical Cancer Research 26 (2020): 3578-3588.

[397] A. S. Zimmer, E. Nichols, A. Cimino-Mathews, et al., “A Phase I Study of the PD-L1 Inhibitor, Durvalumab, in Combination With a PARP Inhibitor, Olaparib, and a VEGFR1-3 Inhibitor, Cediranib, in Recurrent Women's Cancers With Biomarker Analyses,” Journal for Immunotherapy of Cancer 7 (2019): 197.

[398] A. Pandey, K. Roos, Y. Jiang, et al., “Characteristics of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients With Durable Responses to Maveropepimut-S, Pembrolizumab, and Cyclophosphamide: Long-Term Follow-Up From the SPiReL Trial,” EJHaem 6 (2025): e1062.

[399] A. Vergnenegre, I. Monnet, A. Bizieux, et al., “Open-Label Phase II Trial to Evaluate Safety and Efficacy of Second-Line Metronomic Oral Vinorelbine-Atezolizumab Combination for Stage-IV Non-Small-Cell Lung Cancer-VinMetAtezo Trial,(GFPC‡ 04-2017),” Future Oncology 16 (2020): 5-10.

[400] N. L. Williams, E. J. Wuthrick, H. Kim, et al., “Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases,” International Journal of Radiation and Oncology in Biology and Physics 99 (2017): 22-30.

[401] E. J. Lehrer, J. Peterson, P. D. Brown, et al., “Treatment of Brain Metastases With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors: An International Meta-Analysis of Individual Patient Data,” Radiotherapy and Oncology 130 (2019): 104-112.

[402] D. Chen, B. Zou, B. Li, et al., “Adebrelimab Plus Chemotherapy and Sequential Thoracic Radiotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial,” EClinicalMedicine 75 (2024): 102795.

[403] A. Bang, T. J. Wilhite, L. R. G. Pike, et al., “Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy,” International Journal of Radiation and Oncology in Biology and Physics 98 (2017): 344-351.

[404] A. G. Duffy, O. V. Makarova-Rusher, D. E. Kleiner, et al., “A Pilot Study of Immune Checkpoint Inhibition in Combination With Radiation Therapy in Patients With Metastatic Pancreatic Cancer,” Journal of Clinical Oncology 35 (2017): e15786-e15786.

[405] W. L. Hwang, L. R. G. Pike, T. J. Royce, B. A. Mahal, and J. S. Loeffler, “Safety of Combining Radiotherapy With Immune-Checkpoint Inhibition,” Nature Reviews Clinical Oncology 15 (2018): 477-494.

[406] L. F. Spurr, C. A. Martinez, W. Kang, et al., “Highly Aneuploid Non-Small Cell Lung Cancer Shows Enhanced Responsiveness to Concurrent Radiation and Immune Checkpoint Blockade,” Nature Cancer 3 (2022): 1498-1512.

[407] L. Rached, A. Laparra, M. Sakkal, et al., “Toxicity of Immunotherapy Combinations With Chemotherapy Across Tumor Indications: Current Knowledge and Practical Recommendations,” Cancer Treatment Reviews 127 (2024): 102751.

[408] L. Horn, A. S. Mansfield, A. Szczęsna, et al., “First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer,” New England Journal of Medicine 379 (2018): 2220-2229.

[409] L. Paz-Ares, M. Dvorkin, Y. Chen, et al., “Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial,” Lancet 394 (2019): 1929-1939.

[410] I. Le Jeune, J. Gribbin, J. West, C. Smith, P. Cullinan, and R. Hubbard, “The Incidence of Cancer in Patients With Idiopathic Pulmonary Fibrosis and Sarcoidosis in the UK,” Respiratory Medicine 101 (2007): 2534-2540.

[411] M. R. Ferreira, A. Muls, D. P. Dearnaley, and H. J. Andreyev, “Microbiota and Radiation-Induced Bowel Toxicity: Lessons From Inflammatory Bowel Disease for the Radiation Oncologist,” The Lancet Oncology 15 (2014): e139-e147.

[412] S. G. Kroeze, C. Fritz, M. Hoyer, et al., “Toxicity of Concurrent Stereotactic Radiotherapy and Targeted Therapy or Immunotherapy: A Systematic Review,” Cancer Treatment Reviews 53 (2017): 25-37.

[413] P. Bhave, A. Hong, S. N. Lo, et al., “Efficacy and Toxicity of Adjuvant Radiotherapy in Recurrent Melanoma After Adjuvant Immunotherapy,” Journal for ImmunoTherapy of Cancer 11, no. 3 (2023): e006629.

[414] U. M. Cytlak, D. P. Dyer, J. Honeychurch, K. J. Williams, M. A. Travis, and T. M. Illidge, “Immunomodulation by Radiotherapy in Tumour Control and Normal Tissue Toxicity,” Nature Reviews Immunology 22 (2022): 124-138.

[415] D. E. Citrin, “Recent Developments in Radiotherapy,” New England Journal of Medicine 377 (2017): 1065-1075.

[416] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 68 (2018): 394-424.

[417] O. Mahamud, J. So, M. L. K. Chua, and R. G. Bristow, “Targeting DNA Repair for Precision Radiotherapy: Balancing the Therapeutic Ratio,” Current Problems in Cancer 41 (2017): 265-272.

[418] M. A. Morgan, T. S. Lawrence, “Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways,” Clinical Cancer Research 21 (2015): 2898-2904.

[419] V. Yazbeck, E. Alesi, J. Myers, M. H. Hackney, L. Cuttino, and D. A. Gewirtz, “An Overview of Chemotoxicity and Radiation Toxicity in Cancer Therapy,” Advances in Cancer Research 155 (2022): 1-27.

[420] M. A. Postow, R. Sidlow, M. D. Hellmann, “Immune-Related Adverse Events Associated With Immune Checkpoint Blockade,” New England Journal of Medicine 378 (2018): 158-168.

[421] R. J. Sullivan, J. S. Weber, “Immune-Related Toxicities of Checkpoint Inhibitors: Mechanisms and Mitigation Strategies,” Nat Rev Drug Discovery 21 (2022): 495-508.

[422] D. B. Johnson, J. M. Balko, M. L. Compton, et al., “Fulminant Myocarditis With Combination Immune Checkpoint Blockade,” New England Journal of Medicine 375 (2016): 1749-1755.

[423] A. V. Gudkov, E. A. Komarova, “The Role of p53 in Determining Sensitivity to Radiotherapy,” Nature Reviews Cancer 3 (2003): 117-129.

[424] E. Firat, C. Tsurumi, S. Gaedicke, J. Huai, and G. Niedermann, “Tripeptidyl Peptidase II Plays a Role in the Radiation Response of Selected Primary Cell Types but Not Based on Nuclear Translocation and p53 Stabilization,” Cancer Research 69 (2009): 3325-3331.

[425] H. Yu, H. Shen, Y. Yuan, et al., “Deletion of Puma Protects Hematopoietic Stem Cells and Confers Long-Term Survival in Response to High-Dose Gamma-Irradiation,” Blood 115 (2010): 3472-3480.

[426] F. Paris, Z. Fuks, A. Kang, et al., “Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice,” Science 293 (2001): 293-297.

[427] B. P. Venkatesulu, L. S. Mahadevan, M. L. Aliru, et al., “Radiation-Induced Endothelial Vascular Injury: A Review of Possible Mechanisms,” JACC: Basic to Translational Science 3 (2018): 563-572.

[428] S. Bodo, C. Campagne, T. H. Thin, et al., “Single-Dose Radiotherapy Disables Tumor Cell Homologous Recombination via Ischemia/Reperfusion Injury,” Journal of Clinical Investigation 129 (2019): 786-801.

[429] D. Cardinale, A. Colombo, M. T. Sandri, et al., “Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition,” Circulation 114 (2006): 2474-2481.

[430] R. Zajączkowska, M. Kocot-Kępska, W. Leppert, A. Wrzosek, J. Mika, and J. Wordliczek, “Mechanisms of Chemotherapy-Induced Peripheral Neuropathy,” International Journal of Molecular Sciences 20, no. 6 (2019): 1451.

[431] L. Gu, P. A. Khadaroo, H. Su, et al., “The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (anti-PD-1/PD-L1 Plus Anti-CTLA-4): A Systematic Review and Meta-Analysis,” BMC Cancer 19 (2019): 559.

[432] J. S. Weber, F. S. Hodi, J. D. Wolchok, et al., “Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma,” Journal of Clinical Oncology 35 (2017): 785-792.

[433] K. Haratani, H. Hayashi, Y. Chiba, et al., “Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer,” JAMA Oncology 4 (2018): 374-378.

[434] I. Puzanov, A. Diab, K. Abdallah, et al., “Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group,” Journal for ImmunoTherapy of Cancer 5 (2017): 95.

[435] M. S. von Itzstein, S. Khan, D. E. Gerber, “Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis,” Clinical Chemistry 66 (2020): 779-793.

[436] A. Diehl, M. Yarchoan, A. Hopkins, E. Jaffee, and S. A. Grossman, “Relationships Between Lymphocyte Counts and Treatment-Related Toxicities and Clinical Responses in Patients With Solid Tumors Treated With PD-1 Checkpoint Inhibitors,” Oncotarget 8 (2017): 114268-114280.

[437] Y. Fujisawa, K. Yoshino, A. Otsuka, et al., “Fluctuations in Routine Blood Count Might Signal Severe Immune-Related Adverse Events in Melanoma Patients Treated With Nivolumab,” Journal of Dermatological Science 88 (2017): 225-231.

[438] S. Kimbara, Y. Fujiwara, S. Iwama, et al., “Association of Antithyroglobulin Antibodies With the Development of Thyroid Dysfunction Induced by Nivolumab,” Cancer Science 109 (2018): 3583-3590.

[439] C. Ma, F. S. Hodi, A. Giobbie-Hurder, et al., “The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders,” Cancer Immunology Research 7 (2019): 1214-1220.

[440] T. Hirashima, T. Kanai, H. Suzuki, et al., “The Levels of Interferon-Gamma Release as a Biomarker for Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors,” Anticancer Research 39 (2019): 6231-6240.

[441] S. Khan, S. A. Khan, X. Luo, et al., “Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events,” British Journal of Cancer 120 (2019): 63-68.

[442] K. R. Wells, C. M. Amato, J. Hintzsche, and W. Robinson, “Identification of Somatic Mutations to Predict Development of Autoimmune Adverse Events to Immune Therapy in Melanoma,” Journal of Clinical Oncology 34 (2016): 3041-3041.

[443] K. Dubin, M. K. Callahan, B. Ren, et al., “Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis,” Nature Communications 7 (2016): 10391.

[444] N. Chaput, P. Lepage, C. Coutzac, et al., “Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab,” Annals of Oncology 28 (2017): 1368-1379.

[445] A. M. Stamatouli, Z. Quandt, A. L. Perdigoto, et al., “Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors,” Diabetes 67 (2018): 1471-1480.

[446] V. Shahabi, D. Berman, S. D. Chasalow, et al., “Gene Expression Profiling of Whole Blood in Ipilimumab-Treated Patients for Identification of Potential Biomarkers of Immune-Related Gastrointestinal Adverse Events,” Journal of Translational Medicine 11 (2013): 75.

[447] D. Azria, M. Ozsahin, A. Kramar, et al., “Single Nucleotide Polymorphisms, Apoptosis, and the Development of Severe Late Adverse Effects After Radiotherapy,” Clinical Cancer Research 14 (2008): 6284-6288.

[448] S. Chaouni, D. D. Lecomte, D. Stefan, et al., “The Possibility of Using Genotoxicity, Oxidative Stress and Inflammation Blood Biomarkers to Predict the Occurrence of Late Cutaneous Side Effects After Radiotherapy,” Antioxidants (Basel) 9, no. 3 (2020): 220.

[449] J. Weidhaas, N. Marco, A. W. Scheffler, et al., “Germline Biomarkers Predict Toxicity to Anti-PD1/PDL1 Checkpoint Therapy,” Journal for ImmunoTherapy of Cancer 10, no. 2 (2022): e003625.

[450] S. Trebeschi, S. G. Drago, N. J. Birkbak, et al., “Predicting Response to Cancer Immunotherapy Using Noninvasive Radiomic Biomarkers,” Annals of Oncology 30 (2019): 998-1004.

[451] I. Dokic, M. Niklas, F. Zimmermann, et al., “Correlation of Particle Traversals With Clonogenic Survival Using Cell-Fluorescent Ion Track Hybrid Detector,” Frontiers in Oncology 5 (2015): 275.

[452] M. Niklas, S. Greilich, C. Melzig, et al., “Engineering Cell-Fluorescent Ion Track Hybrid Detectors,” Radiation Oncology 8 (2013): 141.

[453] D. W. M. Walsh, H. Liew, J. Schlegel, A. Mairani, A. Abdollahi, and M. Niklas, “Carbon Ion Dosimetry on a Fluorescent Nuclear Track Detector Using Widefield Microscopy,” Physics in Medicine and Biology 65 (2020): 21nt02.

[454] A. Pantelias, D. Zafiropoulos, R. Cherubini, et al., “Interphase Cytogenetic Analysis of G0 Lymphocytes Exposed to α-Particles, C-Ions, and Protons Reveals Their Enhanced Effectiveness for Localized Chromosome Shattering-A Critical Risk for Chromothripsis,” Cancers (Basel) 12, no. 9 (2020): 2336.

[455] Y. Yoshimoto, K. Kono, Y. Suzuki, “Anti-Tumor Immune Responses Induced by Radiotherapy: A Review,” Fukushima Journal of Medical Science 61 (2015): 13-22.

[456] G. Baldacchino, E. Brun, I. Denden, et al., “Importance of Radiolytic Reactions During High-LET Irradiation Modalities: LET Effect, Role of O2 and Radiosensitization by Nanoparticles,” Cancer Nanotechnology 10 (2019): 3.

[457] R. Alan Mitteer, Y. Wang, J. Shah, et al., “Proton Beam Radiation Induces DNA Damage and Cell Apoptosis in Glioma Stem Cells Through Reactive Oxygen Species,” Scientific Reports 5 (2015): 13961.

[458] A. G. Georgakilas, P. O'Neill, R. D. Stewart, “Induction and Repair of Clustered DNA Lesions: What Do We Know so Far?,” Radiation Research 180 (2013): 100-109.

[459] D. Marcus, R. I. Y. Lieverse, C. Klein, et al., “Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy,” Cancers (Basel) 13, no. 6 (2021): 1468.

[460] Y. Takahashi, T. Yasui, K. Minami, et al., “Carbon Ion Irradiation Enhances the Antitumor Efficacy of Dual Immune Checkpoint Blockade Therapy Both for Local and Distant Sites in Murine Osteosarcoma,” Oncotarget 10 (2019): 633-646.

[461] W. Mu, Q. Chu, Y. Liu, and N. Zhang, “A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy,” Nano-Micro Letters 12 (2020): 1-24.

[462] C. G. Da Silva, F. Rueda, C. W. Löwik, F. Ossendorp, and L. J. Cruz, “Combinatorial Prospects of Nano-Targeted Chemoimmunotherapy,” Biomaterials 83 (2016): 308-320.

[463] T. Shao, X. Li, J. Ge, “Target Drug Delivery System as a New Scarring Modulation After Glaucoma Filtration Surgery,” Diagnostic Pathology 6 (2011): 64.

[464] J. A. Kemp, M. S. Shim, C. Y. Heo, and Y. J. Kwon, ““Combo” Nanomedicine: Co-Delivery of Multi-Modal Therapeutics for Efficient, Targeted, and Safe Cancer Therapy,” Advanced Drug Delivery Reviews 98 (2016): 3-18.

[465] R. X. Zhang, H. L. Wong, H. Y. Xue, J. Y. Eoh, and X. Y. Wu, “Nanomedicine of Synergistic Drug Combinations for Cancer Therapy—Strategies and Perspectives,” Journal of Controlled Release 240 (2016): 489-503.

[466] R. Kuai, W. Yuan, S. Son, et al., “Elimination of Established Tumors With Nanodisc-Based Combination Chemoimmunotherapy,” Science Advances 4 (2018): eaao1736.

[467] M. B. Heo, S. Y. Kim, W. S. Yun, and Y. T. Lim, “Sequential Delivery of an Anticancer Drug and Combined Immunomodulatory Nanoparticles for Efficient Chemoimmunotherapy,” International Journal of Nanomedicine 10 (2015): 5981-5992.

[468] F. Zhou, B. Feng, H. Yu, et al., “Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade,” Advanced Materials 31 (2019): e1805888.

[469] L. Monney, C. A. Sabatos, J. L. Gaglia, et al., “Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease,” Nature 415 (2002): 536-541.

[470] L. Gattinoni, X. S. Zhong, D. C. Palmer, et al., “Wnt Signaling Arrests Effector T Cell Differentiation and Generates CD8+ Memory Stem Cells,” Nature Medicine 15 (2009): 808-813.

[471] J. E. Kim, M. A. Patel, A. Mangraviti, et al., “Combination Therapy With Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas,” Clinical Cancer Research 23 (2017): 124-136.

[472] K. J. Kim, H. W. Lee, J. Seong, “Combination Therapy With Anti-T-Cell Immunoglobulin and Mucin-Domain Containing Molecule 3 and Radiation Improves Antitumor Efficacy in Murine Hepatocellular Carcinoma,” Journal of Gastroenterology and Hepatology 36 (2021): 1357-1365.

[473] Á. de Mingo Pulido, A. Gardner, S. Hiebler, et al., “TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer,” Cancer Cell 33 (2018): 60-74.

[474] J. Li, M. McCloskey, C. Jennings, S. Pachhal, E. Greer, A. Chin, E. Geoghegan, Q. Liang, J. Hwang, and M. Roy, Antibody radioconjugates in combination with CD47 immunotherapy improves antitumor efficacy in preclinical models of solid tumors, Society of Nuclear Medicine, 2022.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.